How many Tocilizumab clinical trials are there?

466 Tocilizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 54 are actively recruiting participants. 258 are marked completed.

Are Tocilizumab clinical trials recruiting in 2026?

Yes — 54 Tocilizumab trials are actively recruiting in 2026, with 191 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Tocilizumab being studied for?

Tocilizumab is being studied for Rheumatoid Arthritis, COVID-19, Juvenile Idiopathic Arthritis, Giant Cell Arteritis, Multiple Myeloma and 426 more. The trials are grouped by indication on this page.

What phase is Tocilizumab in?

Tocilizumab clinical trials span 53 Phase 4, 130 Phase 3, 99 Phase 2, 64 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Tocilizumab clinical trials?

The lead sponsor across the most Tocilizumab trials is Hoffmann-La Roche, with 199 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Tocilizumab Clinical Trials (2026): 466 Studies for Rheumatoid Arthritis & COVID-19

Creator: Hipa.ai Research
Published: 2026-05-20T23:37:39.889Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 16, 2026.

466 Tocilizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 192 indications (including Rheumatoid Arthritis & COVID-19) and 282,043 total planned enrollment. 130 Phase 3 Tocilizumab trials and 99 Phase 2, 53 Phase 4 are listed. 68 Tocilizumab clinical trials are actively recruiting at 191 U.S. sites across 33 states. Most recent activity: NCT07594067 (Jul 2042).

Where to Participate: All Tocilizumab Trial Sites in the U.S. (191 sites across 33 states)

Every actively recruiting Tocilizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Children's Hospital of Alabama	Birmingham35233	NCT05533775	Map
AL	University of Alabama_6th Ave	Birmingham35294	NCT03564340	Map
AZ	Phoenix Children's Hospital /ID# 253403	Phoenix85016-7710	NCT05609630	Map
AZ	St. Joseph's Hospital and Medical Center (Site #: 71192)	Phoenix85013	NCT06033196	Map
AZ	Arizona Oncology Associates	Tucson85711	NCT05972135	Map
CA	Cedars Sinai Medical Center (Site #: 71146)	Beverly Hills90211	NCT06033196	Map
CA	UC Irvine Medical Center	Costa Mesa92627	NCT04524871	Map
CA	City of Hope	Duarte91010	NCT04524871	Map
CA	City of Hope Cancer Center	Duarte91010	NCT06084936	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06624085	Map
CA	University of California-San Diego Medical Center	La Jolla92093	NCT03511118	Map
CA	Saddleback Memorial Medical Center	Laguna Hills92653	NCT06624085	Map
CA	Loma Linda University Health	Loma Linda92354	NCT03511118	Map
CA	David Geffen School of Medicine at UCLA (Site #: 71123)	Los Angeles90095	NCT06033196	Map
CA	Kaiser Permanente Oakland Medical Center	Oakland94611	NCT05533775	Map
CA	UCSF Benioff Children's Hospital Oakland	Oakland94609	NCT05533775	Map
CA	UC Irvine Medical Center	Orange92868	NCT04524871	Map
CA	Kaiser Permanente - Roseville	Roseville95661	NCT05533775	Map
CA	University of California San Diego Medical Center	San Diego92103	NCT04524871	Map
CA	UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program	San Francisco94143	NCT05169515	Map
CA	University of California San Francisco Cancer Center	San Francisco94115	NCT04524871	Map
CA	University of California San Francisco Pediatric Rheumatology	San Francisco94158	NCT06654882	Map
CA	University of California, San Francisco	San Francisco94143	NCT03821246	Map
CA	University of San Francisco, California	San Francisco94143	NCT03708224	Map
CA	Kaiser Permanente - Santa Clara	Santa Clara95051	NCT05533775	Map
CA	UCLA Center for East	Santa Monica90404	NCT04524871	Map
CA	University of California Los Angeles (UCLA) - Cancer Care - Santa Monica	Santa Monica90404-2023	NCT06084936	Map
CA	University of California Los Angeles (UCLA) - Cancer Care - Santa Monica	Santa Monica90404-2023	NCT06624085	Map
CO	Cherry Creek Medical Center	Aurora80045	NCT04524871	Map
CO	Children's Hospital Colorado	Aurora80045	NCT05233397	Map
CO	University of Colorado	Aurora80045	NCT05169515	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT05869955	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT07335562	Map
CO	University of Colorado Hospital - Anschutz Cancer Pavilion	Aurora80045	NCT04524871	Map
CO	Colorado Blood Cancer Institute	Denver80218	NCT05869955	Map
CO	Colorado Blood Cancer Institute	Denver80218	NCT05972135	Map
CO	Rocky Mountain Cancer Center	Denver80218	NCT05972135	Map
CO	UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital	Highlands Ranch80129-6694	NCT04524871	Map
CT	Smilow Cancer Hospital at Yale New Haven	New Haven06510	NCT04524871	Map
CT	Yale Cancer Center	New Haven06520	NCT06084936	Map
DE	Medical Oncology Hematology Consultants	Newark19713	NCT05972135	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT05233397	Map
DC	Childrens National Medical Center /ID# 253344	Washington D.C.20010-2916	NCT05609630	Map
DC	Georgetown University	Washington D.C.20007	NCT06084936	Map
DC	Georgetown University	Washington D.C.20007	NCT06624085	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT04524871	Map
FL	University of Miami	Coral Gables33146	NCT06084936	Map
FL	University of Florida	Gainesville32610	NCT06654882	Map
FL	University of Florida Health (UF Health)	Gainesville32608	NCT06863480	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT05869955	Map
FL	University of Florida	Jacksonville32209	NCT02735707	Map
FL	University of Miami Hospital and Clinics, Sylvester Cancer Center	Miami33136	NCT05869955	Map
FL	AdventHealth Cancer Institute	Orlando32804	NCT06624085	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05169515	Map
GA	Emory University	Atlanta30322	NCT05846789	Map
GA	Emory University School of Medicine	Atlanta30322	NCT07335562	Map
GA	Emory University School of Medicine: Division of Rheumatology	Atlanta30307	NCT07108387	Map
GA	Winship Cancer Institute at Emory University	Atlanta30322	NCT06043674	Map
GA	Winship Cancer Institute of Emory University	Atlanta30329	NCT06624085	Map
IL	Ann and Robert H. Lurie Childrens Hospital of Chicago	Chicago60614	NCT03511118	Map
IL	Northwestern University	Chicago60611	NCT07108387	Map
IL	The University of Chicago	Chicago60637	NCT05169515	Map
IL	University of Chicago	Chicago60637	NCT05640271	Map
IL	University of Illinois Cancer Center	Chicago60612	NCT06624085	Map
IL	University of Illinois Health	Chicago60612	NCT02735707	Map
IN	IU Health Joe and Shelly Schwarz Cancer Center	Carmel46032	NCT05846789	Map
IN	Indiana University Melvin and Bren Simon Comprehensive Cancer Center	Indianapolis46202	NCT05846789	Map
IN	Sidney and Lois Eskenazi Hospital	Indianapolis46202	NCT05846789	Map
KS	Kansas City VA Medical Center	Kansas City64128	NCT06624085	Map
KY	University of Kentucky - Markey Cancer Center	Lexington40536-7001	NCT04524871	Map
MD	Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center	Baltimore21287	NCT07108387	Map
MD	Johns Hopkins University	Baltimore21231	NCT05533775	Map
MD	Walter Reed National Military Medical Center	Bethesda20814	NCT06624085	Map
MD	Maryland Oncology Hematology	Columbia21044	NCT05972135	Map
MA	Brigham and Women's Hospital	Boston02215	NCT06043674	Map
MA	Brigham And Womens Hospital	Boston02115	NCT07115745	Map
MA	Dana Farber / Harvard Cancer Center	Boston02215	NCT03564340	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06043674	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05533775	Map
MA	Massachusetts General Hospital	Boston02114	NCT03564340	Map
MA	Massachusetts General Hospital (Site #: 71107)	Boston02114	NCT06033196	Map
MA	Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases	Boston02114	NCT07108387	Map
MA	University of Massachusetts Chan Medical School	Worcester01655	NCT05869955	Map
MI	University of Michigan	Ann Arbor48109	NCT02735707	Map
MI	University of Michigan	Ann Arbor48109-2800	NCT05869955	Map
MI	University of Michigan Health System	Ann Arbor48109	NCT06084936	Map
MI	Henry Ford Medical Center - New Center One	Detroit48202	NCT05869955	Map
MN	Children's Hospital and Clinics - Minneapolis	Minneapolis55404	NCT03511118	Map
MN	Minnesota Oncology Hematology	Minneapolis55404	NCT05972135	Map
MN	Mayo Clinic - Rochester	Rochester55901	NCT03564340	Map
MN	Mayo Clinic in Rochester, Minnesota	Rochester55905	NCT05869955	Map
MN	Mayo Clinic Rochester	Rochester55902	NCT05091424	Map
MO	St. Luke's Hospital	Chesterfield63017	NCT06084936	Map
MO	Childrens Mercy Hosp & Clinics	Kansas City64108	NCT05533775	Map
MO	Alvin J. Siteman Cancer Center at Washington University	St Louis63110	NCT03821246	Map
MO	Barnes Jewish Hospital/ Washington University SOM (Site #: 71191)	St Louis63110	NCT06033196	Map
MO	Washington University School of Medicine	St Louis63110	NCT05869955	Map
NV	Renown Regional Medical Center	Reno89502	NCT06084936	Map
NJ	Hackensack Meridian Health - Joseph M. Sanzari Children's Hospital	Hackensack07601	NCT06654882	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06084936	Map
NJ	Atlantic Health System Overlook Medical Center	Summit07901	NCT05869955	Map
NM	Christus Health - Christus St. Vincent Regional Medical Center	Santa Fe87505	NCT06624085	Map
NY	Roswell Park Comprehensive Cancer Center	Buffalo14203	NCT05846789	Map
NY	Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology	Great Neck11021	NCT07108387	Map
NY	Columbia University Irving Medical Center	New York10032	NCT05869955	Map
NY	Columbia University Medical Center	New York10032	NCT03564340	Map
NY	Columbia University Medical Center (Site #: 71113)	New York10032	NCT06033196	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT05869955	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT07493317	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT02735707	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT03564340	Map
NY	MSKCC	New York10065	NCT05533775	Map
NY	NYU Langone Health	New York10016	NCT05869955	Map
NY	University of Rochester	Rochester14642	NCT06084936	Map
NY	Stony Brook Univ Cancer Ctr	Stony Brook11794	NCT06624085	Map
NY	New York Medical College /ID# 253437	Valhalla10595	NCT05609630	Map
NC	The University of North Carolina at Chapel Hill	Chapel Hill27599	NCT05869955	Map
NC	The University of North Carolina at Chapel Hill	Chapel Hill27599	NCT06043674	Map
NC	Levine Cancer Institute	Charlotte28204	NCT05169515	Map
NC	Duke Children's Hospital	Durham27710	NCT05233397	Map
NC	Duke University	Durham27708	NCT05846789	Map
NC	Duke University	Durham27705-2771	NCT07115745	Map
NC	Duke University Maternal and Fetal Medicine	Durham27705	NCT03511118	Map
NC	Duke University Medical Center (Site #: 71139)	Durham27710	NCT06033196	Map
NC	Virginia Oncology Associates	Elizabeth City27909	NCT05972135	Map
NC	East Carolina University	Greenville27834	NCT06624085	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05533775	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05233397	Map
OH	Cincinnati Childrens Hospital Medical Center /ID# 251827	Cincinnati45229	NCT05609630	Map
OH	Oncology Hematology Care	Cincinnati45242	NCT05972135	Map
OH	Cleveland Clinic	Cleveland44195	NCT05869955	Map
OH	Cleveland Clinic (Site #: 71101)	Cleveland44195	NCT06033196	Map
OH	Nationwide Children's Hospital	Columbus43235	NCT05233397	Map
OH	Nationwide Children's Hospital	Columbus43205	NCT06654882	Map
OH	Ohio State University Medical Center (Site #: 71196)	Columbus43210	NCT06033196	Map
OH	The James Cancer Hospital and Solove Research Institute	Columbus43210	NCT05091424	Map
OH	The Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06043674	Map
OH	The Ohio State University Wexner Medical Center	Columbus43210	NCT02735707	Map
OH	The Ohio State University Wexner Medical Center James Comprehensive Cancer Center	Hilliard43026	NCT03564340	Map
OK	Stephenson Cancer Center	Oklahoma City73104	NCT03564340	Map
OR	Oncology Associates of Oregon	Eugene97401	NCT05972135	Map
OR	Oregon Health & Science University	Portland97239	NCT03511118	Map
OR	Oregon Health & Science University	Portland97239	NCT04524871	Map
OR	Oregon Health and Science University	Portland97239-3098	NCT02735707	Map
OR	Randall Children's Hospital /ID# 251829	Portland97227-1654	NCT05609630	Map
PA	Abramson Cancer Center of the University of Pennsylvania	Philadelphia19104	NCT04691817	Map
PA	Thomas Jefferson University	Philadelphia19107	NCT06624085	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06941376	Map
PA	Allegheny Health Network Cancer Institute	Pittsburgh15213	NCT06016179	Map
PA	University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology	Pittsburgh15217	NCT07108387	Map
PA	University of Pittsburgh Medical Centre	Pittsburgh	NCT02735707	Map
PA	University of Pittsburgh School of Medicine	Pittsburgh15213	NCT03511118	Map
TN	Tennessee Oncology - Chattanooga Oncology & Hematology Associates	Chattanooga37404	NCT03424005	Map
TN	The West Clinic	Germantown38138	NCT03424005	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT03564340	Map
TN	Tennessee Oncology PLLC	Nashville37203	NCT03424005	Map
TN	TriStar Bone Marrow Transplant	Nashville37203	NCT05972135	Map
TN	Vanderbilt University Medical Center	Nashville37212	NCT03424005	Map
TN	Vanderbilt- Ingram Cancer Center	Nashville37232	NCT05972135	Map
TX	Texas Tech University Health Sciences Center School of Medicine.	Amarillo79106	NCT03511118	Map
TX	Texas Oncology	Austin78705	NCT05972135	Map
TX	Parkland Health & Hospital System	Dallas75235	NCT04524871	Map
TX	The University of Texas Southwestern Medical Center at Dallas	Dallas75390	NCT04524871	Map
TX	University of Texas Southwestern (Site #: 71187)	Dallas75390	NCT06033196	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT05869955	Map
TX	Renovatio Clinical - El Paso	El Paso79915	NCT06084936	Map
TX	Renovatio Clinical - El Paso	El Paso79915	NCT06624085	Map
TX	University of Texas Medical Branch - Galveston	Galveston77555	NCT03511118	Map
TX	Baylor College of Medicine	Houston77030	NCT06624085	Map
TX	Texas Children's Hospital	Houston77030	NCT05233397	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT05869955	Map
TX	The Women's Hospital of Texas	Houston77054	NCT03511118	Map
TX	University of Texas Health Science Center at Houston	Houston77030	NCT03511118	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT05869955	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05169515	Map
TX	Texas Oncology - San Antonio	San Antonio78240	NCT05972135	Map
TX	University of Texas Health Science Center	San Antonio78229	NCT03511118	Map
TX	Renovatio Clinical	The Woodlands77380	NCT06084936	Map
TX	Renovatio Clinical	The Woodlands77380	NCT06624085	Map
TX	Texas Oncology - Northeast Texas	Tyler75702	NCT05972135	Map
UT	Huntsman Cancer Institute at The University of Utah	Salt Lake City84112	NCT05091424	Map
UT	University of Utah	Salt Lake City84132	NCT03511118	Map
UT	University of Utah Medical Center (Site #: 71126)	Salt Lake City84132	NCT06033196	Map
VA	University of Virginia	Charlottesville22906	NCT06084936	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT05972135	Map
VA	Virginia Commonwealth University	Richmond23219	NCT03564340	Map
VA	Blue Ridge Cancer Center	Roanoke24014	NCT05972135	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT05869955	Map
WA	Seattle Children's Hospital	Seattle98105	NCT05233397	Map
WA	Swedish Medical Center	Seattle98104	NCT05869955	Map
WV	West Virginia University	Morgantown26506	NCT06084936	Map

Tocilizumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	no longer available	Total
Early P1		1				1					2
P1	10	7		31	9	1		3	3		64
P1/P2	6	7	1	12	5	1		1	3		36
P2	17	10		34	15	5	1	6	11		99
P2/P3	1	1		5	1				1		9
P3	11	6		94	6	1		3	9		130
P4	5			29	6	2			11		53
N/A	3			53	2		1	1	12	1	73

Recruiting Tocilizumab clinical trials (68)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07594067	TCR1188-ABC Cells in KRAS-mutated Cancers	P1	Cholangiocarcinoma	30	Jul 2026
NCT04381936	RECOVERYRandomised Evaluation of COVID-19 Therapy	P3	Pneumonia	70,000	Mar 2020
NCT05833763	GOlDiLOXA Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.	P2	Mantle Cell Lymphoma	42	Oct 2023
NCT07570173	MK-1045-005A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)	P2/P3	B-cell Acute Lymphoblastic Leukemia	340	May 2026
NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	P2	Chronic Lymphocytic Leukemia	70	Jan 2024
NCT05533775	iMATRIX GLOA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	P1/P2	Mature B-Cell Non-Hodgkin Lymphoma	65	Nov 2022
NCT05091424	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia	P1	Chronic Lymphocytic Leukemia	137	Mar 2022
NCT07573332	BMS-086353A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients	P1	AQP4+ NMOSD	5	Jun 2026
NCT06381661	PALETTEAdaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial	P2	Sepsis	2,000	May 2026
NCT07493317	ILNeutralizing Interleukin (IL)-6	P2	Major Depressive Disorder	60	Mar 2026
NCT07335562	Breakfree-SScA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis	P3	Systemic Sclerosis	92	Aug 2026
NCT07589634	TRI ProA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma	P2	Multiple Myeloma	230	Jul 2026
NCT07281027	COMBAT-NORSECOMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"	P3	New Onset Refractory Status Epilepticus	438	Jul 2026
NCT03424005	Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	Metastatic Breast Cancer	792	Mar 2018
NCT07115745	A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases	P1	Refractory Autoimmune Diseases	125	Sep 2025
NCT07392814	TOCIVENAStudy With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia	P1	Leukemia Acute Myeloid - AML	12	Mar 2026
NCT06624085	A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P1	Lymphoma	50	Apr 2025
NCT07108387	Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis	P2	Giant Cell Arteritis (GCA)	78	Dec 2025
NCT05233397	ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma	P2	Adamantinomatous Craniopharyngioma	30	Dec 2022
NCT07254637	TociCCAreTocilizumab in Chronic Inflammatory CPPD Disease	P2	Calcium Pyrophosphate Deposition Disease	80	Apr 2026
NCT05169515	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	P1	Non-Hodgkin Lymphoma	121	Oct 2022
NCT07113743	Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease	P1/P2	Chronic Granulomatous Disease (CGD)	10	Sep 2025
NCT06447701	IRIS-sICASInterleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis	P3	Brain Diseases	486	Oct 2025
NCT05609630	SELECT-sJIAStudy of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	P3	Juvenile Idiopathic Arthritis	90	Oct 2023
NCT04871191	SATELITEStudy of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	P3	Granulomatosis With Polyangiitis	42	Jun 2025
NCT06033196	ALL IN LUNGTocilizumab in Lung Transplantation	P2	Lung Transplant	350	Feb 2024
NCT04561986	INTERCEPTTocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients	P3	Antibody-mediated Rejection	50	Feb 2022
NCT06016517	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	—	Arthritis, Rheumatoid	18	May 2026
NCT06934044	A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma	P1	Multiple Myeloma	20	May 2025
NCT07595900	Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis	P1/P2	Granulomatous Lobular Mastitis	31	Jun 2026
NCT06863480	THRIVETocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events	P1	Aneurysmal Subarachnoid Hemorrhage	30	Mar 2026
NCT05869955	A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	P1	Systemic Lupus Erythematosus	270	Sep 2023
NCT05583617	PLYCOMA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma	P1/P2	Multiple Myeloma	200	Nov 2023
NCT03511118	Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants	—	Lactating Women on Select DOI	1,600	Oct 2018
NCT07052058	SUSTriple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)	P2	Treatment-Resistant Major Depressive Disorder	32	Jul 2026
NCT03708224	Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck	P2	Cancer	55	Mar 2019
NCT06084936	GLOBRYTEA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma	P3	Lymphoma	182	Oct 2023
NCT06297096	NINTOC-TUStudy of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease	P3	Systemic Sclerosis	86	Jul 2025
NCT02735707	REMAP-CAPRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	P3	Community-acquired Pneumonia, Influenza, COVID-19	20,000	Apr 2016
NCT06941376	PROSECT RPAn Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis	P2	Relapsing Polychondritis	20	Aug 2025
NCT05972135	Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma	P2	Multiple Myeloma	100	Oct 2023
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	Rheumatic Disease	80	Sep 2025
NCT04691817	Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy	P1/P2	Lung Cancer, Nonsmall Cell	28	Jul 2023
NCT04524871	MORPHEUS-LIVERA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	P1/P2	Advanced Liver Cancers	518	Nov 2020
NCT06818266	TOCIACSEfficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease	P3	Sickle Cell Disease	130	Apr 2025
NCT05927571	A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)	P1	Relapsed or Refractory Multiple Myeloma	120	Aug 2023
NCT05874505	UVB"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"	P2	Behcet's Uveitis	60	Jul 2023
NCT06430736	PRONTOPRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)	P2	Myeloma	100	Jul 2024
NCT06498089	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	P4	Takayasu Arteritis	124	Jun 2024
NCT05845723	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	P2	Aneurysm	81	Jun 2023
NCT03564340	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	P1/P2	Recurrent Ovarian Cancer	890	May 2018
NCT07006532	Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab	N/A	Kidney Transplant Rejection	50	Jan 2025
NCT03821246	Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy	P2	Prostate Adenocarcinoma	68	Oct 2019
NCT07509645	IRIS-3Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke	P3	Ischemic Stroke	348	Apr 2026
NCT07334379	IDENTIFYInterleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study	P2	Acute Hypoxemic Respiratory Failure	60	Oct 2025
NCT06016179	RIOT2Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer	P1	Malignant Pleural Effusion	12	Jan 2024
NCT05640271	Tocilizumab for Acute Chest Syndrome	P2	Sickle Cell Disease	200	Apr 2023
NCT06654882	SMART-JIATrial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	P3	Polyarticular Course Juvenile Idiopathic Arthritis (JIA)	400	Jan 2026
NCT05846789	SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers	P2	Metastatic Breast Cancer	168	Jul 2024
NCT07377058	PROMIS-MDA5RCT of Tocilizumab for Anti-MDA5+DM	N/A	Dermatomyositis	110	Nov 2025
NCT06251076	Plan Development for Giving Teclistamab in the Outpatient Setting	P4	Multiple Myeloma	15	Nov 2024
NCT04088396	LY3009104A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)	P3	Systemic Juvenile Idiopathic Arthritis	58	Feb 2020
NCT06426160	TOPACTocilizumab for Painful Chronic Pancreatitis	P2	Pancreatitis, Chronic	36	May 2024
NCT05067348	tMGEfficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis	P2	Myasthenia Gravis, Generalized	64	Jul 2022
NCT06927375	A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy	P4	Thyroid-Associated Ophthalmopathy	60	Dec 2024
NCT06624436	DEDICATE-LPSImmunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia	P4	Sepsis	52	Oct 2024
NCT05333302	Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma	P1	B-cell Acute Lymphoblastic Leukemia	10	Oct 2020
NCT04300686	A Pilot Study in Severe Patients With Takayasu Arteritis.	P4	Takayasu Arteritis	40	Mar 2020

Tocilizumab clinical trials by indication

Rheumatoid Arthritis (141)

NCT	Acronym	Phase	Status	Title
NCT02765074	REPAIR	P4	completed	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis
NCT03440892	SurviTreat	N/A	unknown	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients
NCT03895879	TODORA	P4	unknown	Use of Tocilizumab Drug Levels to Optimize Treatment in RA
NCT04449224	—	N/A	unknown	Comparative Effectiveness of Targeted Therapy in RA Patients
NCT06418529	—	N/A	completed	A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
NCT05090410	TRANSFORM	P3	unknown	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
NCT05725434	—	P3	unknown	A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis
NCT04885829	—	P1	completed	Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
+ 133 more, see All trials below.

COVID-19 (19)

NCT	Acronym	Phase	Status	Title
NCT05925140	LUSZ_AVIST	P1	unknown	LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
NCT04479358	COVIDOSE-2	P2	terminated	Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
NCT04321993	COVID-19	P2	unknown	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
NCT05164133	—	P1	completed	A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
NCT06233357	CasiTocCOVID	N/A	completed	Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application
NCT05638932	—	N/A	completed	Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
NCT04377659	—	P2	terminated	Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
NCT05082714	—	N/A	completed	Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
+ 11 more, see All trials below.

Juvenile Idiopathic Arthritis (15)

NCT	Acronym	Phase	Status	Title
NCT05609630	SELECT-sJIA	P3	recruiting	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT03301883	—	P4	completed	A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT02165345	—	P1	completed	Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
NCT02840175	AJIBIOREM	P3	completed	Treatment Tapering in JIA With Inactive Disease
NCT01734382	—	P4	completed	A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
NCT01455701	—	P1	completed	A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT01904292	—	P1	completed	A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
NCT01904279	JIGSAW 117	P1	completed	A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
+ 7 more, see All trials below.

Giant Cell Arteritis (13)

NCT	Acronym	Phase	Status	Title
NCT06037460	MAGICA	P3	active not recruiting	TocilizuMab discontinuAtion in GIant Cell Arteritis
NCT03892785	METOGiA	P3	active not recruiting	MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
NCT04888221	TOGIAC	P3	active not recruiting	Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
NCT05168475	BIOVAS	P2	terminated	Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
NCT04239196	TOCIAION	P2	unknown	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
NCT03726749	—	P4	completed	Tocilizumab Plus a Short Prednisone Taper for GCA
NCT03745586	GUSTO	P1/P2	completed	Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
NCT03923738	TCZ	P1	completed	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
+ 5 more, see All trials below.

Multiple Myeloma (11)

NCT	Acronym	Phase	Status	Title
NCT07589634	TRI Pro	P2	not yet recruiting	A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT04910568	CAMMA 1	P1	active not recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06934044	—	P1	recruiting	A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT05583617	PLYCOM	P1/P2	recruiting	A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
NCT05972135	—	P2	recruiting	Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05535244	CAMMA 2	P1/P2	active not recruiting	A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05646836	—	P1	active not recruiting	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
NCT06251076	—	P4	recruiting	Plan Development for Giving Teclistamab in the Outpatient Setting
+ 3 more, see All trials below.

Covid19 (10)

NCT	Acronym	Phase	Status	Title
NCT04424056	INFLAMMACOV	P3	unknown	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
NCT04600141	HEPMAB	P3	completed	Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
NCT04734678	—	N/A	completed	Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome
NCT04423042	—	P3	unknown	Tocilizumab in Coronavirus-19 Positive Patients
NCT04779047	—	P4	unknown	Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
NCT04693026	—	P3	unknown	Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
NCT04678739	—	P3	completed	Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
NCT04435717	COVITOZ-01	P2	terminated	Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
+ 2 more, see All trials below.

Arthritis, Rheumatoid (6)

NCT	Acronym	Phase	Status	Title
NCT06016517	—	N/A	not yet recruiting	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT03227419	SUNSTAR	P4	unknown	Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders
NCT04842981	—	P1/P2	terminated	Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
NCT02843789	ADIPRAT	P4	completed	Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy
NCT02087696	—	P4	unknown	Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
NCT01715831	RITACT	P4	completed	A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488

COVID-19 Pneumonia (6)

NCT	Acronym	Phase	Status	Title
NCT04317092	TOCIVID-19	P2	unknown	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)
NCT05035589	—	N/A	completed	The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
NCT04409262	REMDACTA	P3	completed	A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
NCT04372186	EMPACTA	P3	completed	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
NCT04320615	COVACTA	P3	completed	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
NCT04346355	—	P2	terminated	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

Lymphoma (4)

NCT	Acronym	Phase	Status	Title
NCT06624085	—	P1	recruiting	A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06084936	GLOBRYTE	P3	recruiting	A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT04980222	R	P2	active not recruiting	A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
NCT04657302	—	P1	completed	A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Takayasu Arteritis (4)

NCT	Acronym	Phase	Status	Title
NCT06498089	—	P4	recruiting	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
NCT03893136	—	N/A	unknown	The Registry Study of Takayasu Arteritis in East China
NCT04300686	—	P4	recruiting	A Pilot Study in Severe Patients With Takayasu Arteritis.
NCT04564001	INTOReTAK	P2	unknown	Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis

Solid Tumors (4)

NCT	Acronym	Phase	Status	Title
NCT03448042	—	P1	active not recruiting	A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT05129280	—	P1	terminated	A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
NCT02324257	—	P1	completed	A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
NCT03539484	—	P1	terminated	A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Pneumonia, Viral (4)

NCT	Acronym	Phase	Status	Title
NCT04394182	ULTRA-COVID	N/A	suspended	Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
NCT04380818	—	N/A	unknown	Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19
NCT04347031	—	P2/P3	completed	A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
NCT04519385	—	N/A	completed	Toclizumam Versus Dexamethasone in Severe Covid-19 Cases

Systemic Juvenile Idiopathic Arthritis (4)

NCT	Acronym	Phase	Status	Title
NCT04088396	LY3009104	P3	recruiting	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144612	—	P3	completed	Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144664	—	P3	completed	Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144599	—	P3	completed	Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Major Depressive Disorder (3)

NCT	Acronym	Phase	Status	Title
NCT07493317	IL	P2	recruiting	Neutralizing Interleukin (IL)-6
NCT03787290	WBH	P2	suspended	Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder
NCT02660528	—	P2	terminated	Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Systemic Sclerosis (3)

NCT	Acronym	Phase	Status	Title
NCT07335562	Breakfree-SSc	P3	recruiting	A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT06297096	NINTOC-TU	P3	recruiting	Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
NCT02453256	focuSSced	P3	completed	A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

B-cell Acute Lymphoblastic Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT07570173	MK-1045-005	P2/P3	recruiting	A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT03467256	—	P1/P2	unknown	CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
NCT05333302	—	P1	recruiting	Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Relapsing Polychondritis (3)

NCT	Acronym	Phase	Status	Title
NCT06941376	PROSECT RP	P2	recruiting	An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
NCT01104480	—	P2	withdrawn	Tocilizumab for Relapsing Polychondritis
NCT01041248	—	N/A	completed	Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab

Systemic Lupus Erythematosus (3)

NCT	Acronym	Phase	Status	Title
NCT05869955	—	P1	recruiting	A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05835986	—	P1	active not recruiting	A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05155345	—	P1	completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Non-Hodgkin Lymphoma (3)

NCT	Acronym	Phase	Status	Title
NCT05169515	—	P1	recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05207670	MorningSun	P2	active not recruiting	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
NCT05171647	SUNMO	P3	active not recruiting	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Cytokine Release Syndrome (3)

NCT	Acronym	Phase	Status	Title
NCT04377503	—	P2	terminated	Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
NCT04873141	CRS	N/A	completed	Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia
NCT03533101	—	P1/P2	completed	Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

Rheumatoid Arthritis (RA) (3)

NCT	Acronym	Phase	Status	Title
NCT03737708	RA	P4	completed	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
NCT02353780	MAZERATI	P4	terminated	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT01258712	—	P3	completed	Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Polymyalgia Rheumatica (3)

NCT	Acronym	Phase	Status	Title
NCT02908217	—	P3	completed	Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
NCT03263715	—	P3	completed	A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
NCT02888496	TENOR-IMMUNO	N/A	completed	Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica

Schizophrenia (3)

NCT	Acronym	Phase	Status	Title
NCT02874573	—	P1	unknown	Tocilizumab in Schizophrenia
NCT02034474	—	P4	completed	Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
NCT01696929	—	P1	completed	An Open-Label Trial of Tocilizumab in Schizophrenia

Healthy Volunteer (3)

NCT	Acronym	Phase	Status	Title
NCT02678988	AI 1000-G2	P1	completed	A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers
NCT01991990	—	P4	completed	A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers
NCT01418989	—	P1	completed	A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Sepsis (2)

NCT	Acronym	Phase	Status	Title
NCT06381661	PALETTE	P2	not yet recruiting	Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
NCT06624436	DEDICATE-LPS	P4	recruiting	Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Dermatomyositis (2)

NCT	Acronym	Phase	Status	Title
NCT07377058	PROMIS-MDA5	N/A	recruiting	RCT of Tocilizumab for Anti-MDA5+DM
NCT02043548	TIM	P2	completed	Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Sickle Cell Disease (2)

NCT	Acronym	Phase	Status	Title
NCT06818266	TOCIACS	P3	not yet recruiting	Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
NCT05640271	—	P2	recruiting	Tocilizumab for Acute Chest Syndrome

Metastatic Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03424005	Morpheus-panBC	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT05846789	—	P2	recruiting	SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Chronic Lymphocytic Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT06043674	—	P2	recruiting	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
NCT05091424	—	P1	recruiting	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Tocilizumab (2)

NCT	Acronym	Phase	Status	Title
NCT06087731	—	P2	withdrawn	Efficacy and Safety of Tocilizumab for TAO
NCT04893031	—	N/A	completed	Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

Myasthenia Gravis, Generalized (2)

NCT	Acronym	Phase	Status	Title
NCT05067348	tMG	P2	recruiting	Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05716035	tMG-E	P2/P3	unknown	Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Adamantinomatous Craniopharyngioma (2)

NCT	Acronym	Phase	Status	Title
NCT05233397	—	P2	recruiting	ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT03970226	—	Early P1	active not recruiting	Tocilizumab in Children With ACP

Pancreatic Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05070247	—	P1/P2	terminated	A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT04258150	TRIPPLE-R	P2	terminated	Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer

Lymphoma, Non-Hodgkin (2)

NCT	Acronym	Phase	Status	Title
NCT04077723	—	P1/P2	active not recruiting	A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05219513	—	P1	terminated	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Kidney Transplantation (2)

NCT	Acronym	Phase	Status	Title
NCT03867617	—	P1/P2	active not recruiting	Cell Therapy for Immunomodulation in Kidney Transplantation
NCT04779957	RAIPONS	P2	completed	Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04871854	—	P2	completed	Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
NCT03135171	—	P1	completed	Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Obesity (2)

NCT	Acronym	Phase	Status	Title
NCT04687540	—	N/A	completed	Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6
NCT03967691	—	N/A	completed	IL-6 Regulation of Substrate Metabolism and Influence of Obesity

Diffuse Large B-cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT04408638	—	P3	active not recruiting	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT03677154	BTCT4465A	P1/P2	completed	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT04688021	—	P2	unknown	A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
NCT02385110	—	P2	completed	Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Acute Myeloid Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT03434730	—	P2	completed	Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
NCT04580121	—	P1	completed	A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Hematologic Malignancy (2)

NCT	Acronym	Phase	Status	Title
NCT04395222	—	P2	active not recruiting	Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
NCT03699631	PROACTIVE	P2	completed	PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Covid-19 (2)

NCT	Acronym	Phase	Status	Title
NCT04412291	—	P2	unknown	A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
NCT04306705	TACOS	N/A	unknown	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19

Solid Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT04082910	—	P1/P2	unknown	Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
NCT03601611	COLAR	N/A	completed	Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

B-cell Non-Hodgkin Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03671018	BTCT4465A	P1/P2	active not recruiting	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
NCT03677141	BTCT4465A	P1/P2	completed	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Recurrent Ovarian Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03564340	—	P1/P2	recruiting	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT01637532	PITCH	P1/P2	completed	Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer

Behcet Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT03554161	—	P2	terminated	Tocilizumab for the Treatment of Refractory Behcet's Uveitis
NCT01693653	—	P2	terminated	Tocilizumab for the Treatment of Behcet's Syndrome

Neuromyelitis Optica Spectrum Disorders (2)

NCT	Acronym	Phase	Status	Title
NCT03350633	TANGO	P2/P3	completed	Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
NCT03062579	—	P1/P2	completed	A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD

Spondylitis, Ankylosing (2)

NCT	Acronym	Phase	Status	Title
NCT01209689	TNF	P3	terminated	A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
NCT01209702	—	P3	terminated	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07594067	—	P1	not yet recruiting	TCR1188-ABC Cells in KRAS-mutated Cancers

New Onset Refractory Status Epilepticus (1)

NCT	Acronym	Phase	Status	Title
NCT07281027	COMBAT-NORSE	P3	not yet recruiting	COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

Treatment-Resistant Major Depressive Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT07052058	SUS	P2	not yet recruiting	Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

AQP4+ NMOSD (1)

NCT	Acronym	Phase	Status	Title
NCT07573332	BMS-086353	P1	not yet recruiting	A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients

Granulomatous Lobular Mastitis (1)

NCT	Acronym	Phase	Status	Title
NCT07595900	—	P1/P2	not yet recruiting	Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis

Calcium Pyrophosphate Deposition Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07254637	TociCCAre	P2	not yet recruiting	Tocilizumab in Chronic Inflammatory CPPD Disease

Ischemic Stroke (1)

NCT	Acronym	Phase	Status	Title
NCT07509645	IRIS-3	P3	recruiting	Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke

Leukemia Acute Myeloid - AML (1)

NCT	Acronym	Phase	Status	Title
NCT07392814	TOCIVENA	P1	not yet recruiting	Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia

Aneurysmal Subarachnoid Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT06863480	THRIVE	P1	recruiting	Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

Polyarticular Course Juvenile Idiopathic Arthritis (JIA) (1)

NCT	Acronym	Phase	Status	Title
NCT06654882	SMART-JIA	P3	recruiting	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

Giant Cell Arteritis (GCA) (1)

NCT	Acronym	Phase	Status	Title
NCT07108387	—	P2	recruiting	Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Acute Ischemic Stroke (1)

NCT	Acronym	Phase	Status	Title
NCT07263776	IRIS-2	P3	active not recruiting	Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

Brain Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT06447701	IRIS-sICAS	P3	not yet recruiting	Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

Acute Hypoxemic Respiratory Failure (1)

NCT	Acronym	Phase	Status	Title
NCT07334379	IDENTIFY	P2	recruiting	Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study

Rheumatic Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07138898	—	P2	not yet recruiting	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Chronic Granulomatous Disease (CGD) (1)

NCT	Acronym	Phase	Status	Title
NCT07113743	—	P1/P2	enrolling by invitation	Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

Refractory Autoimmune Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT07115745	—	P1	recruiting	A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Granulomatosis With Polyangiitis (1)

NCT	Acronym	Phase	Status	Title
NCT04871191	SATELITE	P3	recruiting	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Healthy (1)

NCT	Acronym	Phase	Status	Title
NCT06721910	IGLU	N/A	completed	Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis

Kidney Transplant Rejection (1)

NCT	Acronym	Phase	Status	Title
NCT07006532	—	N/A	recruiting	Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Thyroid-Associated Ophthalmopathy (1)

NCT	Acronym	Phase	Status	Title
NCT06927375	—	P4	recruiting	A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

Refractory Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06372574	—	P1	withdrawn	A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06452537	TOMATO	P2/P3	active not recruiting	Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT06430736	PRONTO	P2	recruiting	PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Pancreatitis, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT06426160	TOPAC	P2	recruiting	Tocilizumab for Painful Chronic Pancreatitis

Lung Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT06033196	ALL IN LUNG	P2	recruiting	Tocilizumab in Lung Transplantation

Interleukin-6 (1)

NCT	Acronym	Phase	Status	Title
NCT06238024	IRIS	P2/P3	completed	Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Malignant Pleural Effusion (1)

NCT	Acronym	Phase	Status	Title
NCT06016179	RIOT2	P1	recruiting	Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Mantle Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05833763	GOlDiLOX	P2	recruiting	A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Relapsed or Refractory Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05927571	—	P1	recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Behcet's Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT05874505	UVB	P2	not yet recruiting	"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"

Lung Cancer, Nonsmall Cell (1)

NCT	Acronym	Phase	Status	Title
NCT04691817	—	P1/P2	recruiting	Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05769959	—	P1	terminated	Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Aneurysm (1)

NCT	Acronym	Phase	Status	Title
NCT05845723	—	P2	recruiting	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05619744	—	P1	completed	A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Anatomic Stage IV Breast Cancer AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04616248	—	P1	active not recruiting	In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Mature B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05533775	iMATRIX GLO	P1/P2	recruiting	A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) (1)

NCT	Acronym	Phase	Status	Title
NCT05364424	—	P1	completed	A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Recurrent Plasma Cell Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05391750	—	P1	active not recruiting	Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Severe Fever With Thrombocytopenia Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05604859	SFTS	P4	unknown	Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Epilepsy (1)

NCT	Acronym	Phase	Status	Title
NCT05346666	—	P3	unknown	Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.

Glycogen Depletion (1)

NCT	Acronym	Phase	Status	Title
NCT05349149	REX-6	N/A	completed	IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout

Acute Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT05350592	DOBERMANN	P2	active not recruiting	Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

Diffuse Astrocytoma, IDH-Wildtype (1)

NCT	Acronym	Phase	Status	Title
NCT04729959	—	P2	active not recruiting	Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Antibody-mediated Rejection (1)

NCT	Acronym	Phase	Status	Title
NCT04561986	INTERCEPT	P3	recruiting	TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

Clinical Stage III Cutaneous Melanoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04940299	—	P2	active not recruiting	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Nasopharyngeal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06442709	—	N/A	unknown	Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Severe COVID 19 Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04924829	—	N/A	unknown	Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19

Orbitopathy, Graves (1)

NCT	Acronym	Phase	Status	Title
NCT06367517	—	N/A	completed	Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

Interleukin-6 Inhibition (1)

NCT	Acronym	Phase	Status	Title
NCT04616235	—	N/A	completed	Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade

Rapid Progressive Interstitial Lung Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT05181397	—	P2	unknown	The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases

COVID-19 Virus Infection (1)

NCT	Acronym	Phase	Status	Title
NCT05133635	—	P4	withdrawn	High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

Esophageal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04554771	BASALT	P2	active not recruiting	Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

Acute Myeloid Leukemia (AML) (1)

NCT	Acronym	Phase	Status	Title
NCT04547062	Tocilam	P1	completed	Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

Advanced Liver Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT04524871	MORPHEUS-LIVER	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Cutaneous Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04551352	TYRP1	P1	completed	A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

COVID-19 Severe Respiratory Failure (1)

NCT	Acronym	Phase	Status	Title
NCT05279391	—	N/A	unknown	Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Immune-related Adverse Events (1)

NCT	Acronym	Phase	Status	Title
NCT04375228	—	P2	active not recruiting	Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

COVID19 (1)

NCT	Acronym	Phase	Status	Title
NCT04361032	TRONCHER	P3	unknown	Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Follicular Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04246086	—	P1/P2	active not recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Corona Virus Disease 2019 (COVID-19) (1)

NCT	Acronym	Phase	Status	Title
NCT04690920	—	N/A	completed	Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Carcinoma, Hepatocellular (1)

NCT	Acronym	Phase	Status	Title
NCT04338685	—	P1	completed	A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Coronavirus Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04476979	TOCIDEX	P2	completed	Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

Chronic Periaortitis (1)

NCT	Acronym	Phase	Status	Title
NCT05133895	—	N/A	completed	Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Idiopathic Retroperitoneal Fibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT04762784	—	P4	unknown	A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04313608	—	P1	completed	A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Sars-CoV2 (1)

NCT	Acronym	Phase	Status	Title
NCT04363853	—	P2	active not recruiting	Tocilizumab Treatment in Patients With COVID-19

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04370834	—	P2	terminated	Tocilizumab for Patients With Cancer and COVID-19 Disease

COVID (1)

NCT	Acronym	Phase	Status	Title
NCT04403685	TOCIBRAS	P3	terminated	Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

SARS-CoV Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04560205	TC19LGH	P1	unknown	Tocilizumab in COVID-19 Lahore General Hospital

SARS-CoV-2 Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04335071	CORON-ACT	P2	terminated	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

SARS-CoV 2 (1)

NCT	Acronym	Phase	Status	Title
NCT04356937	—	P3	completed	Efficacy of Tocilizumab on Patients With COVID-19

CoVid 19 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT04349410	FMTVDM	P2/P3	completed	The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

Covid19 Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04377750	—	P4	unknown	The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

Cerebrovascular Accident (1)

NCT	Acronym	Phase	Status	Title
NCT04361552	—	P3	withdrawn	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04115423	—	N/A	unknown	A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab

Corona Virus Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04331808	CORIMUNO-TOC	P2	completed	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04381936	RECOVERY	P3	recruiting	Randomised Evaluation of COVID-19 Therapy

SARS Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04315480	COVID-19	P2	unknown	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

GCA (1)

NCT	Acronym	Phase	Status	Title
NCT05394909	TOPAZIO	N/A	completed	Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients

Steroid Refractory GVHD (1)

NCT	Acronym	Phase	Status	Title
NCT04070781	GVHD	P1	terminated	Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

Graves Ophthalmopathy (1)

NCT	Acronym	Phase	Status	Title
NCT04876534	TOGO	P2	unknown	Tocilizumab in Active Moderate-severe Graves' Orbitopathy

Living-Donor Kidney Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT04066114	—	P1/P2	completed	Treg Modulation With CD28 and IL-6 Receptor Antagonists

Prostate Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03821246	—	P2	recruiting	Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

CD19 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT04007029	—	P1	active not recruiting	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT03999749	—	P2	active not recruiting	A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03869190	MORPHEUS-UC	P1/P2	completed	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03866239	—	P1	terminated	A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03708224	—	P2	recruiting	Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Heart Arrest (1)

NCT	Acronym	Phase	Status	Title
NCT03863015	IMICA	P2	completed	IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

Heart Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT03644667	—	P2	completed	Tocilizumab in Cardiac Transplantation

Lactating Women on Select DOI (1)

NCT	Acronym	Phase	Status	Title
NCT03511118	—	N/A	recruiting	Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Acute Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03588936	—	P1	terminated	Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

End-stage Renal Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03507348	—	N/A	terminated	Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Non-Hodgkins Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03533283	—	P1/P2	active not recruiting	An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Familial Mediterranean Fever (1)

NCT	Acronym	Phase	Status	Title
NCT03446209	—	P2	completed	Tocilizumab for the Treatment of Familial Mediterranean Fever

B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03467373	CHOP	P1	completed	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Carcinoma, Non-Small-Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT03337698	Morpheus Lung	P1/P2	terminated	A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Chronic Subdural Hematoma (1)

NCT	Acronym	Phase	Status	Title
NCT03353259	—	P2/P3	terminated	Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery

Pharmacokinetics (1)

NCT	Acronym	Phase	Status	Title
NCT03522012	—	P1	completed	Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

Rheumatoid Arthritis of Knee (1)

NCT	Acronym	Phase	Status	Title
NCT03215407	—	P4	unknown	The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone

Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02997956	HCC	P1/P2	withdrawn	Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Schnitzler's Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT03046381	TOCISCH	P2	completed	Tocilizumab in Patients With Schnitzler's Syndrome

Pancreatic Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03193190	—	P1/P2	completed	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT02929251	RUBI	P2	completed	Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis

Coronary Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03004703	ASSAIL-MI	P2	completed	ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial

Non-Hodgkin's Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03075696	RO7082859	P1/P2	active not recruiting	A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Unresectable Pancreatic Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02767557	PACTO	P2	completed	Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

Arthritis,Rheumatoid (1)

NCT	Acronym	Phase	Status	Title
NCT02963402	—	N/A	completed	Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT02511067	READ-4	P2	withdrawn	Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study

Adiposity (1)

NCT	Acronym	Phase	Status	Title
NCT02901496	—	N/A	completed	Ectopic Adipose Tissue, Exercise Training and IL-6

Lymphoblastic Leukemia, Acute, Childhood (1)

NCT	Acronym	Phase	Status	Title
NCT02906371	—	P1	completed	Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

Community-acquired Pneumonia, Influenza, COVID-19 (1)

NCT	Acronym	Phase	Status	Title
NCT02735707	REMAP-CAP	P3	recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02174263	—	P2	withdrawn	Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Pulmonary Arterial Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT02676947	TRANSFORM-UK	P2	completed	A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

ALS (1)

NCT	Acronym	Phase	Status	Title
NCT02469896	TCZALS-001	P2	completed	A Trial of Tocilizumab in ALS Subjects

Hand Osteoarthritis (1)

NCT	Acronym	Phase	Status	Title
NCT02477059	TIDOA	P3	completed	Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis

B-Cell Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT02336048	B-CLL	P1	terminated	A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT02419937	STAT-MI	N/A	completed	Short-Term Application of Tocilizumab Following Myocardial Infarction

Refractory Diffuse Large B Cell Lymphoma (DLBCL) (1)

NCT	Acronym	Phase	Status	Title
NCT02348216	ZUMA-1	P1/P2	completed	Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Type 1 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT02293837	EXTEND	P2	completed	Tocilizumab (TCZ) in New-onset Type 1 Diabetes

Hematopoietic Stem Cell Transplantation (1)

NCT	Acronym	Phase	Status	Title
NCT02206035	AGVD	P2	completed	A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

HIV Infections (1)

NCT	Acronym	Phase	Status	Title
NCT02049437	IL-6	P1/P2	completed	AIDS 347: IL-6 Blockade in Treated HIV Infection

Late Complication From Kidney Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT02108600	—	P2	completed	Tocilizumab for Renal Graft Inflammation

TAKAYASU ARTERITIS (1)

NCT	Acronym	Phase	Status	Title
NCT02101333	TOCITAKA	P3	completed	Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Leukemia, Myeloid, Acute (1)

NCT	Acronym	Phase	Status	Title
NCT02057770	—	P1	terminated	Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Hemophagocytic Lymphohistiocytosis (1)

NCT	Acronym	Phase	Status	Title
NCT02007239	HLH	P2	withdrawn	Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

Juvenile Idiopathic Arthritis Associated Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT01603355	—	P1/P2	terminated	Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

Primary Sjögren's Syndrome (pSS) (1)

NCT	Acronym	Phase	Status	Title
NCT01782235	ETAP	P2/P3	completed	Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

Fibrous Dysplasia of Bone (1)

NCT	Acronym	Phase	Status	Title
NCT01791842	TOCIDYS	P2	completed	TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE

Intermediate Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT01717170	STOP-Uveitis	P1/P2	unknown	Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

Erdheim-Chester Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01727206	—	P2	terminated	Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease

End Stage Renal Disease (ESRD) (1)

NCT	Acronym	Phase	Status	Title
NCT01594424	—	P1/P2	completed	A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Thyroid Associated Ophthalmopathies (1)

NCT	Acronym	Phase	Status	Title
NCT01297699	GRC	P3	completed	Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

Sclerosis, Systemic (1)

NCT	Acronym	Phase	Status	Title
NCT01532869	—	P3	completed	A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Castleman Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01441063	—	P2	completed	Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Non-ST Elevation Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT01491074	—	P2	completed	Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

Acute Graft Versus Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01475162	—	P1/P2	terminated	Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Polymyalgia Rheumatica (PMR) (1)

NCT	Acronym	Phase	Status	Title
NCT01396317	—	P2	completed	Study of Tocilizumab to Treat Polymyalgia Rheumatica

Diabetes Mellitus, Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT01073826	Exil-6	N/A	completed	Role of Interleukin-6 in Exercise

Adult's Still Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01002781	—	P2	unknown	Efficacy and Safety of Tocilizumab in Adult's Still Disease

Arthritis, Juvenile Rheumatoid (1)

NCT	Acronym	Phase	Status	Title
NCT00868751	—	N/A	terminated	Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

Castleman's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01183598	—	P1	completed	A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

Polyarticular Juvenile Idiopathic Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT00144625	—	P3	completed	Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Tocilizumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
DEDICATE-LPS	NCT06624436	P4	recruiting	Sepsis	52	—
REPAIR	NCT02765074	P4	completed	Rheumatoid Arthritis	60	PMID 20112404
TODORA	NCT03895879	P4	unknown	Rheumatoid Arthritis	98	PMID 28939629
SUNSTAR	NCT03227419	P4	unknown	Arthritis, Rheumatoid	224	PMID 40527572
SFTS	NCT05604859	P4	unknown	Severe Fever With Thrombocytopenia Syndrome	350	—
RAFTING	NCT03100253	P4	terminated	Rheumatoid Arthritis	208	—
RA	NCT03737708	P4	completed	Rheumatoid Arthritis (RA)	21	—
TOLEDO	NCT01557374	P4	completed	Rheumatoid Arthritis	232	—
MAZERATI	NCT02353780	P4	terminated	Rheumatoid Arthritis (RA)	10	—
ADIPRAT	NCT02843789	P4	completed	Arthritis, Rheumatoid	109	PMID 32993784
RASTS	NCT01717859	P4	completed	Rheumatoid Arthritis	74	PMID 34269927
RITACT	NCT01715831	P4	completed	Arthritis, Rheumatoid	26	—
TREMERA	NCT04157010	P4	completed	Rheumatoid Arthritis	20	—
SURPRISE	NCT01120366	P4	completed	Rheumatoid Arthritis	233	PMID 31106666
ROC	NCT01000441	P4	completed	Rheumatoid Arthritis	300	PMID 27654603
ACT-ALONE	NCT01219933	P4	completed	Rheumatoid Arthritis	68	—
MTX	NCT01283971	P4	terminated	Rheumatoid Arthritis	96	—
VISARA	NCT01163747	P4	completed	Rheumatoid Arthritis	91	PMID 24448345
RECOVERY	NCT04381936	P3	recruiting	Pneumonia	70,000	PMID 38296965
Breakfree-SSc	NCT07335562	P3	recruiting	Systemic Sclerosis	92	—
COMBAT-NORSE	NCT07281027	P3	not yet recruiting	New Onset Refractory Status Epilepticus	438	—
IRIS-sICAS	NCT06447701	P3	not yet recruiting	Brain Diseases	486	—
SELECT-sJIA	NCT05609630	P3	recruiting	Juvenile Idiopathic Arthritis	90	—
SATELITE	NCT04871191	P3	recruiting	Granulomatosis With Polyangiitis	42	PMID 27338776
INTERCEPT	NCT04561986	P3	recruiting	Antibody-mediated Rejection	50	PMID 38519988
MAGICA	NCT06037460	P3	active not recruiting	Giant Cell Arteritis	120	PMID 41067765
GLOBRYTE	NCT06084936	P3	recruiting	Lymphoma	182	—
NINTOC-TU	NCT06297096	P3	recruiting	Systemic Sclerosis	86	PMID 29529897
REMAP-CAP	NCT02735707	P3	recruiting	Community-acquired Pneumonia, Influenza, COVID-19	20,000	PMID 37039790
TOCIACS	NCT06818266	P3	not yet recruiting	Sickle Cell Disease	130	—
IRIS-3	NCT07509645	P3	recruiting	Ischemic Stroke	348	—
SUNMO	NCT05171647	P3	active not recruiting	Non-Hodgkin Lymphoma	208	PMID 41037766
METOGiA	NCT03892785	P3	active not recruiting	Giant Cell Arteritis	230	PMID 36963127
SMART-JIA	NCT06654882	P3	recruiting	Polyarticular Course Juvenile Idiopathic Arthritis (JIA)	400	—
LY3009104	NCT04088396	P3	recruiting	Systemic Juvenile Idiopathic Arthritis	58	—
IRIS-2	NCT07263776	P3	active not recruiting	Acute Ischemic Stroke	692	—
TOGIAC	NCT04888221	P3	active not recruiting	Giant Cell Arteritis	66	—
TRANSFORM	NCT05090410	P3	unknown	Rheumatoid Arthritis	400	PMID 36869356
INFLAMMACOV	NCT04424056	P3	unknown	Covid19	216	—
MTX	NCT03155347	P3	completed	Rheumatoid Arthritis	340	PMID 40388166
HEPMAB	NCT04600141	P3	completed	Covid19	308	—
COV-AID	NCT04330638	P3	completed	COVID-19	342	PMID 32493441
ARCHITECTS	NCT04412772	P3	terminated	COVID-19	20	—
REMDACTA	NCT04409262	P3	completed	COVID-19 Pneumonia	649	—
TRONCHER	NCT04361032	P3	unknown	COVID19	260	—
AJIBIOREM	NCT02840175	P3	completed	Juvenile Idiopathic Arthritis	62	—
EMPACTA	NCT04372186	P3	completed	COVID-19 Pneumonia	377	PMID 33201228
COVACTA	NCT04320615	P3	completed	COVID-19 Pneumonia	452	PMID 34612846
TOCIBRAS	NCT04403685	P3	terminated	COVID	129	PMID 33472855
TOVERA	NCT02837146	P3	unknown	Rheumatoid Arthritis	45	—
SC	NCT03202368	P3	completed	Giant Cell Arteritis	3	—
TIDOA	NCT02477059	P3	completed	Hand Osteoarthritis	104	—
focuSSced	NCT02453256	P3	completed	Systemic Sclerosis	212	PMID 33538094
TOCITAKA	NCT02101333	P3	completed	TAKAYASU ARTERITIS	18	PMID 32943098
GCA	NCT01791153	P3	completed	Giant Cell Arteritis	251	PMID 34049857
MTX	NCT01855789	P3	completed	Rheumatoid Arthritis	718	PMID 29575803
SC	NCT02046616	P3	completed	Rheumatoid Arthritis	133	PMID 34131623
ACT-MOVE	NCT02046603	P3	completed	Rheumatoid Arthritis	162	PMID 31431998
RA	NCT01941940	P3	completed	Rheumatoid Arthritis	227	—
OSCAR	NCT01987479	P3	completed	Rheumatoid Arthritis	150	—
NCT01007435	NCT01668966	P3	completed	Rheumatoid Arthritis	23	—
TOSCA	NCT02001987	P3	completed	Rheumatoid Arthritis	139	—
GRC	NCT01297699	P3	completed	Thyroid Associated Ophthalmopathies	32	—
RA	NCT01734993	P3	completed	Rheumatoid Arthritis	11	—
NCT01007435	NCT01665430	P3	terminated	Rheumatoid Arthritis	38	—
REGN88	NCT01768572	P3	completed	Rheumatoid Arthritis	202	PMID 34519964
JIA	NCT00642460	P3	completed	Juvenile Idiopathic Arthritis	112	PMID 30824645
SC	NCT01662063	P3	completed	Rheumatoid Arthritis	218	PMID 27747585
ALABASTER	NCT01235507	P3	completed	Rheumatoid Arthritis	71	—
RA	NCT00106535	P3	completed	Rheumatoid Arthritis	1,196	PMID 23945134
TNF	NCT00883753	P3	completed	Rheumatoid Arthritis	934	—
TNF	NCT01209689	P3	terminated	Spondylitis, Ankylosing	113	—
REMISSION	NCT01610791	P3	completed	Rheumatoid Arthritis	121	—
RA	NCT00750880	P3	completed	Rheumatoid Arthritis	1,681	—
ROSE	NCT00531817	P3	completed	Rheumatoid Arthritis	619	PMID 23305631
PICTURE	NCT01063062	P3	completed	Rheumatoid Arthritis	107	—
RA	NCT00144586	P3	completed	Rheumatoid Arthritis	42	—
RA	NCT00144534	P3	completed	Rheumatoid Arthritis	115	—
RA	NCT00144547	P3	completed	Rheumatoid Arthritis	241	—
RA	NCT00380601	P3	completed	Rheumatoid Arthritis	20	—
RA	NCT00144521	P3	completed	Rheumatoid Arthritis	127	—
RA	NCT00144508	P3	completed	Rheumatoid Arthritis	306	—
GOlDiLOX	NCT05833763	P2	recruiting	Mantle Cell Lymphoma	42	—
PALETTE	NCT06381661	P2	not yet recruiting	Sepsis	2,000	—
IL	NCT07493317	P2	recruiting	Major Depressive Disorder	60	—
TRI Pro	NCT07589634	P2	not yet recruiting	Multiple Myeloma	230	—
TociCCAre	NCT07254637	P2	not yet recruiting	Calcium Pyrophosphate Deposition Disease	80	—
WBH	NCT03787290	P2	suspended	Major Depressive Disorder	35	PMID 27172277
ALL IN LUNG	NCT06033196	P2	recruiting	Lung Transplant	350	—
SUS	NCT07052058	P2	not yet recruiting	Treatment-Resistant Major Depressive Disorder	32	—
BASALT	NCT04554771	P2	active not recruiting	Esophageal Adenocarcinoma	41	—
PROSECT RP	NCT06941376	P2	recruiting	Relapsing Polychondritis	20	—
UVB	NCT05874505	P2	not yet recruiting	Behcet's Uveitis	60	—
MorningSun	NCT05207670	P2	active not recruiting	Non-Hodgkin Lymphoma	320	—
PRONTO	NCT06430736	P2	recruiting	Myeloma	100	—
IDENTIFY	NCT07334379	P2	recruiting	Acute Hypoxemic Respiratory Failure	60	—
R	NCT04980222	P2	active not recruiting	Lymphoma	46	PMID 41979332
TOPAC	NCT06426160	P2	recruiting	Pancreatitis, Chronic	36	—
tMG	NCT05067348	P2	recruiting	Myasthenia Gravis, Generalized	64	—
DOBERMANN	NCT05350592	P2	active not recruiting	Acute Myocardial Infarction	100	PMID 39501388
COVIDOSE-2	NCT04479358	P2	terminated	COVID-19	85	PMID 32488861
RAIPONS	NCT04779957	P2	completed	Kidney Transplantation	18	—
COVID-19	NCT04321993	P2	unknown	COVID-19	363	—
TOCIVID-19	NCT04317092	P2	unknown	COVID-19 Pneumonia	402	PMID 33031955
TOGO	NCT04876534	P2	unknown	Graves Ophthalmopathy	64	PMID 18613843
BIOVAS	NCT05168475	P2	terminated	Giant Cell Arteritis	22	—
INTOReTAK	NCT04564001	P2	unknown	Takayasu Arteritis	50	—
PROACTIVE	NCT03699631	P2	completed	Hematologic Malignancy	29	PMID 36106394
PACTO	NCT02767557	P2	completed	Unresectable Pancreatic Carcinoma	147	PMID 40354592
TOCIAION	NCT04239196	P2	unknown	Giant Cell Arteritis	58	—
RUBI	NCT02929251	P2	completed	Uveitis	112	PMID 41643758
TRIPPLE-R	NCT04258150	P2	terminated	Pancreatic Cancer	26	PMID 36592507
TOCIDEX	NCT04476979	P2	completed	Coronavirus Infection	453	PMID 35350097
TOCOVID	NCT04332094	P2	unknown	COVID-19	276	—
COPERNICO	NCT04335305	P2	terminated	COVID-19	12	—
HLH	NCT02007239	P2	withdrawn	Hemophagocytic Lymphohistiocytosis	0	PMID 23678006
COVITOZ-01	NCT04435717	P2	terminated	Covid19	26	—
ASSAIL-MI	NCT03004703	P2	completed	Coronary Disease	200	PMID 37591633
ESCAPE	NCT04339712	P2	completed	COVID-19	102	—
CORIMUNO-TOC	NCT04331808	P2	completed	Corona Virus Infection	228	PMID 34028504
CORON-ACT	NCT04335071	P2	terminated	SARS-CoV-2 Infection	5	PMID 32171076
EXTEND	NCT02293837	P2	completed	Type 1 Diabetes Mellitus	136	PMID 27629486
IMICA	NCT03863015	P2	completed	Heart Arrest	80	PMID 39510308
COVIDOSE	NCT04331795	P2	completed	COVID-19	32	PMID 33210302
COVID-19	NCT04315480	P2	unknown	SARS Pneumonia	38	PMID 33307107
TIM	NCT02043548	P2	completed	Dermatomyositis	36	PMID 17394136
TOCISCH	NCT03046381	P2	completed	Schnitzler's Syndrome	8	PMID 33545397
AGVD	NCT02206035	P2	completed	Hematopoietic Stem Cell Transplantation	45	PMID 17845118
TCZALS-001	NCT02469896	P2	completed	ALS	22	PMID 34075589
TOCIDYS	NCT01791842	P2	completed	Fibrous Dysplasia of Bone	19	PMID 35104665
TRANSFORM-UK	NCT02676947	P2	completed	Pulmonary Arterial Hypertension	29	PMID 34588193
READ-4	NCT02511067	P2	withdrawn	Diabetic Macular Edema	0	PMID 3658348
HORTOCI	NCT01910038	P2	completed	Giant Cell Arteritis	20	PMID 30054122
RA	NCT00144651	P2	completed	Rheumatoid Arthritis	135	—

Terminated and withdrawn Tocilizumab trials (57)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT03787290suspendedMild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder
NCT06372574withdrawnA Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
NCT03337698terminatedA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
NCT04479358terminatedLow-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
NCT05070247terminatedA Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT05219513terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05769959terminatedStudy of RO7515629 in Participants With HLA-G Positive Solid Tumors
NCT03866239terminatedA Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
NCT05168475terminatedBiologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
NCT06087731withdrawnEfficacy and Safety of Tocilizumab for TAO
NCT05129280terminatedA Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
NCT04377659terminatedTocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
NCT04842981terminatedInterleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
NCT02997956withdrawnStudy of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
NCT04394182suspendedUltra Low Doses of Therapy With Radiation Applicated to COVID-19
NCT03100253terminatedRheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
NCT04070781terminatedItacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
NCT04258150terminatedIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
NCT03353259terminatedTocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
NCT04335305terminatedCheckpoint Blockade in COVID-19 Pandemic
NCT02007239withdrawnTocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
NCT05133635withdrawnHigh-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
NCT04412772terminatedTrial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
NCT04435717terminatedEfficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
NCT03554161terminatedTocilizumab for the Treatment of Refractory Behcet's Uveitis
NCT04370834terminatedTocilizumab for Patients With Cancer and COVID-19 Disease
NCT04377503terminatedTocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
NCT04335071terminatedTocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
NCT04403685terminatedSafety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
NCT03588936terminatedNivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
NCT02660528terminatedTocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder
NCT04346355terminatedEfficacy of Early Administration of Tocilizumab in COVID-19 Patients
NCT04361552withdrawnTocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
NCT03507348terminatedEvaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates
NCT02659150terminatedEffect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis
NCT03539484terminatedA Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
NCT02353780terminatedMechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT01475162terminatedTocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
NCT02336048terminatedA Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
NCT02057770terminatedAllogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02511067withdrawnRanibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
NCT02447055withdrawnAllogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
NCT02174263withdrawnTocilizumab for Chronic Graft-versus-Host Disease Treatment
NCT01603355terminatedTocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis
NCT01727206terminatedPilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
NCT01878318withdrawnA Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs
NCT01661140terminatedA Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
NCT01665430terminatedA Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
NCT01575769terminatedAn Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
NCT01693653terminatedTocilizumab for the Treatment of Behcet's Syndrome
NCT00845832terminatedA Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
NCT01251120terminatedA Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis
NCT01283971terminatedA Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
NCT01104480withdrawnTocilizumab for Relapsing Polychondritis
NCT01209689terminatedA Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
NCT01209702terminatedA Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
NCT00868751terminatedSingle Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

All Tocilizumab trials (466)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07594067		TCR1188-ABC Cells in KRAS-mutated Cancers	P1	not yet recruiting	30	University of Pennsylvania	Jul 2026
NCT04381936	RECOVERY	Randomised Evaluation of COVID-19 Therapy	P3	recruiting	70,000	University of Oxford	Mar 2020
NCT05833763	GOlDiLOX	A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.	P2	recruiting	42	Australasian Leukaemia and Lymphoma Group	Oct 2023
NCT07570173	MK-1045-005	A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)	P2/P3	recruiting	340	Merck Sharp & Dohme LLC	May 2026
NCT06043674		Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	P2	recruiting	70	Christine Ryan	Jan 2024
NCT05533775	iMATRIX GLO	A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	P1/P2	recruiting	65	Hoffmann-La Roche	Nov 2022
NCT05091424		A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia	P1	recruiting	137	Hoffmann-La Roche	Mar 2022
NCT07573332	BMS-086353	A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients	P1	not yet recruiting	5	University of Texas Southwestern Medical Center	Jun 2026
NCT06381661	PALETTE	Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial	P2	not yet recruiting	2,000	Assistance Publique - Hôpitaux de Paris	May 2026
NCT07493317	IL	Neutralizing Interleukin (IL)-6	P2	recruiting	60	Icahn School of Medicine at Mount Sinai	Mar 2026
NCT07335562	Breakfree-SSc	A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis	P3	recruiting	92	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Aug 2026
NCT07589634	TRI Pro	A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma	P2	not yet recruiting	230	Janssen Research & Development, LLC	Jul 2026
NCT07281027	COMBAT-NORSE	COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"	P3	not yet recruiting	438	Yale University	Jul 2026
NCT03424005	Morpheus-panBC	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	recruiting	792	Hoffmann-La Roche	Mar 2018
NCT04246086		A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma	P1/P2	active not recruiting	237	Hoffmann-La Roche	Aug 2020
NCT07115745		A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases	P1	recruiting	125	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Sep 2025
NCT07392814	TOCIVENA	Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia	P1	not yet recruiting	12	Nantes University Hospital	Mar 2026
NCT03999749		A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma	P2	active not recruiting	71	NYU Langone Health	Jun 2019
NCT06624085		A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	P1	recruiting	50	Hoffmann-La Roche	Apr 2025
NCT07108387		Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis	P2	recruiting	78	National Institute of Allergy and Infectious Diseases (NIAID)	Dec 2025
NCT05233397		ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma	P2	recruiting	30	Nationwide Children's Hospital	Dec 2022
NCT04910568	CAMMA 1	A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma	P1	active not recruiting	126	Genentech, Inc.	Jul 2021
NCT07254637	TociCCAre	Tocilizumab in Chronic Inflammatory CPPD Disease	P2	not yet recruiting	80	Assistance Publique - Hôpitaux de Paris	Apr 2026
NCT05169515		A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	P1	recruiting	121	Hoffmann-La Roche	Oct 2022
NCT07113743		Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease	P1/P2	enrolling by invitation	10	National Institute of Allergy and Infectious Diseases (NIAID)	Sep 2025
NCT06447701	IRIS-sICAS	Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis	P3	not yet recruiting	486	Zhujiang Hospital	Oct 2025
NCT05609630	SELECT-sJIA	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	P3	recruiting	90	AbbVie	Oct 2023
NCT04871191	SATELITE	Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis	P3	recruiting	42	Assistance Publique - Hôpitaux de Paris	Jun 2025
NCT03075696	RO7082859	A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma	P1/P2	active not recruiting	940	Hoffmann-La Roche	Feb 2017
NCT03787290	WBH	Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder	P2	suspended	35	Massachusetts General Hospital	Dec 2026
NCT06033196	ALL IN LUNG	Tocilizumab in Lung Transplantation	P2	recruiting	350	National Institute of Allergy and Infectious Diseases (NIAID)	Feb 2024
NCT04561986	INTERCEPT	TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients	P3	recruiting	50	Vastra Gotaland Region	Feb 2022
NCT06016517		Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	—	not yet recruiting	18	Tufts Medical Center	May 2026
NCT06037460	MAGICA	TocilizuMab discontinuAtion in GIant Cell Arteritis	P3	active not recruiting	120	Centre Hospitalier Universitaire Dijon	May 2024
NCT06934044		A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma	P1	recruiting	20	Hoffmann-La Roche	May 2025
NCT07595900		Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis	P1/P2	not yet recruiting	31	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Jun 2026
NCT06863480	THRIVE	Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events	P1	recruiting	30	University of Florida	Mar 2026
NCT05869955		A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	P1	recruiting	270	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Sep 2023
NCT05583617	PLYCOM	A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma	P1/P2	recruiting	200	Hoffmann-La Roche	Nov 2023
NCT03511118		Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants	—	recruiting	1,600	Duke University	Oct 2018
NCT07052058	SUS	Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)	P2	not yet recruiting	32	Hospital de Clinicas de Porto Alegre	Jul 2026
NCT03867617		Cell Therapy for Immunomodulation in Kidney Transplantation	P1/P2	active not recruiting	12	Thomas Wekerle	Aug 2019
NCT03708224		Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck	P2	recruiting	55	Alain Algazi	Mar 2019
NCT04554771	BASALT	Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy	P2	active not recruiting	41	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Jan 2021
NCT06084936	GLOBRYTE	A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma	P3	recruiting	182	Hoffmann-La Roche	Oct 2023
NCT04408638		A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	P3	active not recruiting	270	Hoffmann-La Roche	Feb 2021
NCT06297096	NINTOC-TU	Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease	P3	recruiting	86	National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland	Jul 2025
NCT02735707	REMAP-CAP	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	P3	recruiting	20,000	UMC Utrecht	Apr 2016
NCT05391750		Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma	P1	active not recruiting	7	Emory University	Oct 2022
NCT06372574		A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors	P1	withdrawn	0	Genentech, Inc.	Sep 2024
NCT04616248		In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors	P1	active not recruiting	14	University of Southern California	Jan 2023
NCT06941376	PROSECT RP	An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis	P2	recruiting	20	University of Pennsylvania	Aug 2025
NCT04940299		Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	P2	active not recruiting	35	M.D. Anderson Cancer Center	Sep 2021
NCT04363853		Tocilizumab Treatment in Patients With COVID-19	P2	active not recruiting	200	Instituto Nacional de Cancerologia de Mexico	Jun 2020
NCT05835986		A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus	P1	active not recruiting	70	Hoffmann-La Roche	Dec 2023
NCT03448042		A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	P1	active not recruiting	123	Genentech, Inc.	Jun 2018
NCT05972135		Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma	P2	recruiting	100	SCRI Development Innovations, LLC	Oct 2023
NCT07138898		Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	not yet recruiting	80	NYU Langone Health	Sep 2025
NCT04691817		Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy	P1/P2	recruiting	28	Abramson Cancer Center at Penn Medicine	Jul 2023
NCT04524871	MORPHEUS-LIVER	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	P1/P2	recruiting	518	Hoffmann-La Roche	Nov 2020
NCT04007029		Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	P1	active not recruiting	24	Jonsson Comprehensive Cancer Center	Oct 2019
NCT06818266	TOCIACS	Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease	P3	not yet recruiting	130	Assistance Publique - Hôpitaux de Paris	Apr 2025
NCT05927571		A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)	P1	recruiting	120	Genentech, Inc.	Aug 2023
NCT05874505	UVB	"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"	P2	not yet recruiting	60	Assistance Publique - Hôpitaux de Paris	Jul 2023
NCT05207670	MorningSun	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies	P2	active not recruiting	320	Genentech, Inc.	Feb 2022
NCT06430736	PRONTO	PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)	P2	recruiting	100	Insel Gruppe AG, University Hospital Bern	Jul 2024
NCT06498089		A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	P4	recruiting	124	Shanghai Zhongshan Hospital	Jun 2024
NCT04395222		Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation	P2	active not recruiting	21	Weill Medical College of Cornell University	Oct 2020
NCT05845723		Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	P2	recruiting	81	Peking Union Medical College Hospital	Jun 2023
NCT03970226		Tocilizumab in Children With ACP	Early P1	active not recruiting	9	University of Colorado, Denver	Sep 2019
NCT03564340		Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	P1/P2	recruiting	890	Regeneron Pharmaceuticals	May 2018
NCT07006532		Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab	N/A	recruiting	50	Shahid Beheshti University of Medical Sciences	Jan 2025
NCT03821246		Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy	P2	recruiting	68	David Oh	Oct 2019
NCT07509645	IRIS-3	Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke	P3	recruiting	348	Capital Medical University	Apr 2026
NCT04077723		A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	P1/P2	active not recruiting	498	Hoffmann-La Roche	Aug 2019
NCT05171647	SUNMO	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	P3	active not recruiting	208	Hoffmann-La Roche	Apr 2022
NCT07334379	IDENTIFY	Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study	P2	recruiting	60	Lorenzo delSorbo	Oct 2025
NCT05535244	CAMMA 2	A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma	P1/P2	active not recruiting	90	Hoffmann-La Roche	Oct 2022
NCT06016179	RIOT2	Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer	P1	recruiting	12	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Jan 2024
NCT05640271		Tocilizumab for Acute Chest Syndrome	P2	recruiting	200	University of Chicago	Apr 2023
NCT03892785	METOGiA	MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	P3	active not recruiting	230	Centre Hospitalier Universitaire Dijon	Jan 2020
NCT06654882	SMART-JIA	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	P3	recruiting	400	Duke University	Jan 2026
NCT05846789		SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers	P2	recruiting	168	Kathy Miller	Jul 2024
NCT04375228		Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)	P2	active not recruiting	8	Columbia University	Sep 2020
NCT05646836		A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma	P1	active not recruiting	90	Genentech, Inc.	Mar 2023
NCT07377058	PROMIS-MDA5	RCT of Tocilizumab for Anti-MDA5+DM	N/A	recruiting	110	Peking Union Medical College Hospital	Nov 2025
NCT06251076		Plan Development for Giving Teclistamab in the Outpatient Setting	P4	recruiting	15	University Health Network, Toronto	Nov 2024
NCT03533283		An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	P1/P2	active not recruiting	211	Hoffmann-La Roche	May 2018
NCT04980222	R	A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma	P2	active not recruiting	46	Hoffmann-La Roche	Mar 2022
NCT04088396	LY3009104	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)	P3	recruiting	58	Eli Lilly and Company	Feb 2020
NCT07263776	IRIS-2	Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2	P3	active not recruiting	692	Capital Medical University	Dec 2025
NCT04729959		Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma	P2	active not recruiting	59	National Cancer Institute (NCI)	Mar 2022
NCT06452537	TOMATO	Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease	P2/P3	active not recruiting	102	Tianjin Medical University General Hospital	Jul 2024
NCT06426160	TOPAC	Tocilizumab for Painful Chronic Pancreatitis	P2	recruiting	36	Soren Schou Olesen	May 2024
NCT03893136		The Registry Study of Takayasu Arteritis in East China	—	unknown	1,000	Shanghai Zhongshan Hospital	Nov 2016
NCT05067348	tMG	Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis	P2	recruiting	64	Tang-Du Hospital	Jul 2022
NCT06927375		A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy	P4	recruiting	60	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Dec 2024
NCT03275103		Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)	P1	completed	355	Genentech, Inc.	Sep 2017
NCT06624436	DEDICATE-LPS	Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia	P4	recruiting	52	Radboud University Medical Center	Oct 2024
NCT05925140	LUSZ_AVIST	LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients	P1	unknown	1,000	Lebanese University	Mar 2020
NCT03869190	MORPHEUS-UC	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	P1/P2	completed	272	Hoffmann-La Roche	Jun 2019
NCT03337698	Morpheus Lung	A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)	P1/P2	terminated	314	Hoffmann-La Roche	Dec 2017
NCT05364424		A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma	P1	completed	43	Hoffmann-La Roche	Nov 2022
NCT03467256		CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL	P1/P2	unknown	18	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	May 2018
NCT05350592	DOBERMANN	Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock	P2	active not recruiting	100	Rigshospitalet, Denmark	Mar 2022
NCT06721910	IGLU	Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis	N/A	completed	26	University Hospital, Basel, Switzerland	Jan 2025
NCT04888221	TOGIAC	Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement	P3	active not recruiting	66	Assistance Publique - Hôpitaux de Paris	Sep 2021
NCT03677154	BTCT4465A	Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma	P1/P2	completed	188	Hoffmann-La Roche	May 2019
NCT03671018	BTCT4465A	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma	P1/P2	active not recruiting	422	Hoffmann-La Roche	Sep 2018
NCT05333302		Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma	P1	recruiting	10	Belarusian Research Center for Pediatric Oncology, Hematology and Immunology	Oct 2020
NCT06367517		Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)	—	completed	32	Medical University of Warsaw	May 2021
NCT03434730		Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation	P2	completed	46	Memorial Sloan Kettering Cancer Center	Feb 2018
NCT02765074	REPAIR	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis	P4	completed	60	Centre Hospitalier Régional d'Orléans	Jun 2016
NCT03644667		Tocilizumab in Cardiac Transplantation	P2	completed	385	National Institute of Allergy and Infectious Diseases (NIAID)	Dec 2018
NCT05619744		A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas	P1	completed	41	Hoffmann-La Roche	Jan 2023
NCT03193190		A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	P1/P2	completed	341	Hoffmann-La Roche	Jul 2017
NCT04479358	COVIDOSE-2	Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19	P2	terminated	85	University of Chicago	Sep 2020
NCT03440892	SurviTreat	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	—	unknown	2,500	Vastra Gotaland Region	Nov 2017
NCT05070247		A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors	P1/P2	terminated	61	Takeda	Apr 2022
NCT05855122		Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients	P4	unknown	48	The First Affiliated Hospital of Soochow University	Apr 2023
NCT05716035	tMG-E	Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis	P2/P3	unknown	64	Tang-Du Hospital	Apr 2023
NCT04688021		A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.	P2	unknown	46	Yi Luo	Dec 2020
NCT03895879	TODORA	Use of Tocilizumab Drug Levels to Optimize Treatment in RA	P4	unknown	98	Reade Rheumatology Research Institute	Mar 2020
NCT05155345		A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus	P1	completed	15	Hoffmann-La Roche	Jan 2022
NCT03467373	CHOP	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	P1	completed	111	Hoffmann-La Roche	Mar 2018
NCT03227419	SUNSTAR	Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders	P4	unknown	224	Lille Catholic University	Jan 2018
NCT06238024	IRIS	Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment	P2/P3	completed	108	Suzhou Municipal Hospital of Anhui Province	Feb 2024
NCT04449224		Comparative Effectiveness of Targeted Therapy in RA Patients	—	unknown	506	Hanyang University	Apr 2020
NCT04779957	RAIPONS	Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy	P2	completed	18	University Hospital, Toulouse	Oct 2021
NCT06418529		A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis	—	completed	21,340	Pfizer	May 2024
NCT05219513		A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	P1	terminated	53	Hoffmann-La Roche	Feb 2022
NCT06442709		Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients	N/A	unknown	100	Affiliated Hospital of Nantong University	Aug 2021
NCT05604859	SFTS	Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)	P4	unknown	350	Qin Ning	Aug 2022
NCT04321993	COVID-19	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	P2	unknown	363	Lisa Barrett	Apr 2020
NCT05164133		A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19	P1	completed	2	Hoffmann-La Roche	Jun 2022
NCT05769959		Study of RO7515629 in Participants With HLA-G Positive Solid Tumors	P1	terminated	3	Hoffmann-La Roche	Jun 2023
NCT03866239		A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma	P1	terminated	47	Hoffmann-La Roche	May 2019
NCT04657302		A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	P1	completed	30	Hoffmann-La Roche	Jan 2021
NCT06233357	CasiTocCOVID	Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application	—	completed	95	University of Ulm	Aug 2021
NCT05090410	TRANSFORM	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	P3	unknown	400	Atsushi Kawakami	Mar 2021
NCT05279391		Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19	N/A	unknown	150	Democritus University of Thrace	Oct 2020
NCT04300686		A Pilot Study in Severe Patients With Takayasu Arteritis.	P4	recruiting	40	Shanghai Zhongshan Hospital	Mar 2020
NCT02874573		Tocilizumab in Schizophrenia	P1	unknown	20	Brian Miller	Sep 2016
NCT04082910		Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells	P1/P2	unknown	30	Chinese PLA General Hospital	Sep 2019
NCT04317092	TOCIVID-19	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	P2	unknown	402	National Cancer Institute, Naples	Mar 2020
NCT04876534	TOGO	Tocilizumab in Active Moderate-severe Graves' Orbitopathy	P2	unknown	64	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Dec 2019
NCT05168475	BIOVAS	Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis	P2	terminated	22	Cambridge University Hospitals NHS Foundation Trust	Jul 2021
NCT05346666		Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.	P3	unknown	50	Damanhour University	Jun 2022
NCT03677141	BTCT4465A	A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma	P1/P2	completed	117	Hoffmann-La Roche	Mar 2019
NCT04564001	INTOReTAK	Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis	P2	unknown	50	Assistance Publique - Hôpitaux de Paris	Sep 2020
NCT05638932		Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments	—	completed	1,442	Aetion, Inc.	Jun 2020
NCT06087731		Efficacy and Safety of Tocilizumab for TAO	P2	withdrawn	0	Sun Yat-sen University	Sep 2023
NCT04066114		Treg Modulation With CD28 and IL-6 Receptor Antagonists	P1/P2	completed	24	National Institute of Allergy and Infectious Diseases (NIAID)	Dec 2019
NCT04580121		A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.	P1	completed	59	Hoffmann-La Roche	Nov 2020
NCT05725434		A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis	P3	unknown	30	Celltrion	Feb 2023
NCT02348216	ZUMA-1	Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma	P1/P2	completed	307	Kite, A Gilead Company	Apr 2015
NCT05129280		A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors	P1	terminated	23	Hoffmann-La Roche	Jan 2022
NCT04885829		Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers	P1	completed	300	Syneos Health	May 2021
NCT04547062	Tocilam	Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)	P1	completed	12	Nantes University Hospital	Dec 2020
NCT03699631	PROACTIVE	PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant	P2	completed	29	Medical College of Wisconsin	Nov 2018
NCT04762784		A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis	P4	unknown	40	Peking Union Medical College Hospital	Jul 2020
NCT02385110		Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis	P2	completed	18	M.D. Anderson Cancer Center	Sep 2015
NCT04338685		A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases	P1	completed	55	Hoffmann-La Roche	Jul 2020
NCT02767557	PACTO	Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients	P2	completed	147	Herlev Hospital	Jan 2017
NCT05133895		Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis	—	completed	12	Peking Union Medical College Hospital	Jul 2020
NCT04239196	TOCIAION	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	P2	unknown	58	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts	Sep 2020
NCT04424056	INFLAMMACOV	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease	P3	unknown	216	Assistance Publique Hopitaux De Marseille	Sep 2020
NCT04377659		Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection	P2	terminated	9	Memorial Sloan Kettering Cancer Center	May 2020
NCT05394909	TOPAZIO	Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients	—	completed	20	Azienda USL Reggio Emilia - IRCCS	Feb 2020
NCT05349149	REX-6	IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout	N/A	completed	30	Helga Ellingsgaard	Apr 2022
NCT04842981		Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis	P1/P2	terminated	3	University of Southern Denmark	May 2021
NCT05181397		The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases	P2	unknown	68	Peking Union Medical College Hospital	Feb 2021
NCT04871854		Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints	P2	completed	100	Beni-Suef University	Apr 2021
NCT03155347	MTX	An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy	P3	completed	340	Hoffmann-La Roche	Aug 2017
NCT03301883		A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)	P4	completed	62	Hoffmann-La Roche	Apr 2018
NCT02997956	HCC	Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)	P1/P2	withdrawn	0	University of Michigan Rogel Cancer Center	Jul 2017
NCT04551352	TYRP1	A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	P1	completed	20	Hoffmann-La Roche	Oct 2020
NCT05082714		Tocilizumab Versus Baricitinib in Patients With Severe COVID-19	N/A	completed	251	University Hospital of Patras	Oct 2021
NCT04394182	ULTRA-COVID	Ultra Low Doses of Therapy With Radiation Applicated to COVID-19	N/A	suspended	15	Fundacion GenesisCare	Apr 2020
NCT05232396		Clinical Study of Single Dose IL-6R mAb Injection in RA Patients	P1	completed	40	Beijing VDJBio Co., LTD.	Mar 2021
NCT02929251	RUBI	Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis	P2	completed	112	Assistance Publique - Hôpitaux de Paris	Jun 2017
NCT04600141	HEPMAB	Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection	P3	completed	308	University of Sao Paulo	Nov 2020
NCT03100253	RAFTING	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation	P4	terminated	208	Mario Negri Institute for Pharmacological Research	Mar 2018
NCT03726749		Tocilizumab Plus a Short Prednisone Taper for GCA	P4	completed	30	Massachusetts General Hospital	Nov 2018
NCT04070781	GVHD	Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease	P1	terminated	1	Columbia University	Jan 2020
NCT02165345		Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis	P1	completed	82	Hoffmann-La Roche	Jul 2014
NCT04258150	TRIPPLE-R	Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer	P2	terminated	26	Herlev Hospital	Apr 2020
NCT05035589		The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia	—	completed	100	Sciberras, Stephen M.D.	Sep 2021
NCT04380818		Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19	N/A	unknown	106	Grupo de Investigación Clínica en Oncología Radioterapia	Jun 2020
NCT04313608		A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma	P1	completed	23	Hoffmann-La Roche	Jun 2020
NCT04616235		Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade	N/A	completed	30	Rigshospitalet, Denmark	Mar 2021
NCT04115423		A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab	—	unknown	9,508	Sungkyunkwan University	Apr 2020
NCT03353259		Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery	P2/P3	terminated	382	Oslo University Hospital	Nov 2017
NCT04529863	DREAM	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept	—	completed	30,432	Brigham and Women's Hospital	Aug 2020
NCT04476979	TOCIDEX	Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19	P2	completed	453	Assistance Publique - Hôpitaux de Paris	Jul 2020
NCT04924829		Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19	—	unknown	300	Hospital Italiano de Buenos Aires	Jun 2021
NCT04687540		Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6	N/A	completed	25	Rigshospitalet, Denmark	Apr 2021
NCT04734678		Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome	—	completed	153	Ain Shams University	Dec 2020
NCT04332094	TOCOVID	Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)	P2	unknown	276	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Apr 2020
NCT04423042		Tocilizumab in Coronavirus-19 Positive Patients	P3	unknown	30	University of Calgary	Jul 2020
NCT04412291		A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study	P2	unknown	120	Karolinska University Hospital	Jun 2020
NCT05302947		COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU	—	completed	154	Pirogov Russian National Research Medical University	Feb 2020
NCT02906371		Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome	P1	completed	80	University of Pennsylvania	Aug 2016
NCT04335305	COPERNICO	Checkpoint Blockade in COVID-19 Pandemic	P2	terminated	12	MedSIR	Apr 2020
NCT02007239	HLH	Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)	P2	withdrawn	0	Children's Hospital of Philadelphia	Dec 2013
NCT04330638	COV-AID	Treatment of COVID-19 Patients With Anti-interleukin Drugs	P3	completed	342	University Hospital, Ghent	Apr 2020
NCT04359667	UHID-COVID19	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	—	unknown	30	University Hospital for Infectious Diseases, Croatia	Jun 2020
NCT04377750		The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation	P4	unknown	500	Hadassah Medical Organization	Apr 2020
NCT04779047		Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.	P4	unknown	150	October 6 University	Oct 2020
NCT05133635		High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19	P4	withdrawn	0	Marmara University	Feb 2021
NCT04893031		Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study	—	completed	213	Karadeniz Technical University	Mar 2020
NCT04412772	ARCHITECTS	Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS	P3	terminated	20	Queen's Medical Center	Jun 2020
NCT04409262	REMDACTA	A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia	P3	completed	649	Hoffmann-La Roche	Jun 2020
NCT04693026		Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients	P3	unknown	150	M Abdur Rahim Medical College and Hospital	Sep 2020
NCT03745586	GUSTO	Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab	P1/P2	completed	18	Insel Gruppe AG, University Hospital Bern	Dec 2018
NCT04678739		Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial	P3	completed	205	M Abdur Rahim Medical College and Hospital	Aug 2020
NCT04435717	COVITOZ-01	Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)	P2	terminated	26	Hospital Universitario Ramon y Cajal	May 2020
NCT03004703	ASSAIL-MI	ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial	P2	completed	200	Oslo University Hospital	Mar 2017
NCT03554161		Tocilizumab for the Treatment of Refractory Behcet's Uveitis	P2	terminated	3	Wenjie Zheng	May 2018
NCT04370834		Tocilizumab for Patients With Cancer and COVID-19 Disease	P2	terminated	1	National Cancer Institute (NCI)	May 2020
NCT04339712	ESCAPE	Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	P2	completed	102	Hellenic Institute for the Study of Sepsis	Apr 2020
NCT03288584		Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis	—	unknown	60	University of Athens	Oct 2017
NCT04560205	TC19LGH	Tocilizumab in COVID-19 Lahore General Hospital	P1	unknown	50	Lahore General Hospital	May 2020
NCT04445272		Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia	P2	completed	495	Fundacion SEIMC-GESIDA	May 2020
NCT04690920		Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins	N/A	completed	200	University of Lahore	Jul 2020
NCT04377503		Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19	P2	terminated	30	Hospital Sao Domingos	May 2020
NCT04347031		A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19	P2/P3	completed	320	Burnasyan Federal Medical Biophysical Center	Apr 2020
NCT03923738	TCZ	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).	P1	completed	24	Hoffmann-La Roche	Aug 2019
NCT02908217		Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE	P3	completed	113	University Hospital, Brest	Feb 2017
NCT04331808	CORIMUNO-TOC	CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)	P2	completed	228	Assistance Publique - Hôpitaux de Paris	Mar 2020
NCT04345445		Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression	P3	unknown	310	University of Malaya	Apr 2020
NCT03446209		Tocilizumab for the Treatment of Familial Mediterranean Fever	P2	completed	30	University Hospital Tuebingen	Apr 2018
NCT01441063		Tocilizumab for KSHV-Associated Multicentric Castleman Disease	P2	completed	8	National Cancer Institute (NCI)	Sep 2011
NCT04361032	TRONCHER	Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia	P3	unknown	260	Abderrahmane Mami Hospital	Sep 2020
NCT02840175	AJIBIOREM	Treatment Tapering in JIA With Inactive Disease	P3	completed	62	Assistance Publique - Hôpitaux de Paris	May 2017
NCT04335071	CORON-ACT	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	P2	terminated	5	Insel Gruppe AG, University Hospital Bern	Apr 2020
NCT04372186	EMPACTA	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	P3	completed	377	Genentech, Inc.	May 2020
NCT04349410	FMTVDM	The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol	P2/P3	completed	1,800	The Camelot Foundation	Apr 2020
NCT02293837	EXTEND	Tocilizumab (TCZ) in New-onset Type 1 Diabetes	P2	completed	136	National Institute of Allergy and Infectious Diseases (NIAID)	Mar 2015
NCT04356937		Efficacy of Tocilizumab on Patients With COVID-19	P3	completed	243	Massachusetts General Hospital	Apr 2020
NCT04519385		Toclizumam Versus Dexamethasone in Severe Covid-19 Cases	N/A	completed	69	South Valley University	Mar 2020
NCT04320615	COVACTA	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia	P3	completed	452	Hoffmann-La Roche	Apr 2020
NCT04403685	TOCIBRAS	Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers	P3	terminated	129	Beneficência Portuguesa de São Paulo	May 2020
NCT04492501		Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan	N/A	completed	600	UNICEF	Apr 2020
NCT03588936		Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant	P1	terminated	2	Medical College of Wisconsin	Sep 2018
NCT03863015	IMICA	IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest	P2	completed	80	Christian Hassager	Mar 2019
NCT02660528		Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder	P2	terminated	3	Brigham and Women's Hospital	Apr 2016
NCT04873141	CRS	Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia	—	completed	24	Shaheed Zulfiqar Ali Bhutto Medical University	Apr 2020
NCT04306705	TACOS	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	—	unknown	120	Tongji Hospital	Feb 2020
NCT03737708	RA	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)	P4	completed	21	Astellas Pharma Korea, Inc.	Feb 2019
NCT04730323		TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience	P4	completed	93	FMH College of Medicine and Dentistry	May 2020
NCT04346355		Efficacy of Early Administration of Tocilizumab in COVID-19 Patients	P2	terminated	126	Azienda USL Reggio Emilia - IRCCS	Mar 2020
NCT04331795	COVIDOSE	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	P2	completed	32	University of Chicago	Apr 2020
NCT04361552		Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	P3	withdrawn	0	Emory University	Apr 2020
NCT03263715		A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)	P3	completed	39	Medical University of Vienna	Nov 2017
NCT04315480	COVID-19	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis	P2	unknown	38	Università Politecnica delle Marche	Mar 2020
NCT04310228		Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019	N/A	unknown	150	Peking University First Hospital	Mar 2020
NCT03967691		IL-6 Regulation of Substrate Metabolism and Influence of Obesity	N/A	completed	22	Rigshospitalet, Denmark	Jun 2019
NCT03135171		Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab	P1	completed	11	University of Michigan Rogel Cancer Center	Jul 2017
NCT03601611	COLAR	Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms	N/A	completed	20	Herlev Hospital	Jan 2019
NCT03781310		Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis	P4	unknown	80	Tel-Aviv Sourasky Medical Center	Dec 2018
NCT02837146	TOVERA	Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis	P3	unknown	45	Maria Stoenoiu	Dec 2015
NCT03291457	COGNOS	A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	—	completed	101	Hoffmann-La Roche	Mar 2017
NCT03507348		Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates	N/A	terminated	8	University Hospital, Grenoble	Jul 2018
NCT02659150		Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	P4	terminated	16	Massachusetts General Hospital	May 2016
NCT01557374	TOLEDO	TOward the Lowest Effective DOse of Abatacept or Tocilizumab	P4	completed	232	Assistance Publique - Hôpitaux de Paris	Apr 2012
NCT01734382		A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)	P4	completed	35	Hoffmann-La Roche	Jun 2013
NCT02324257		A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors	P1	completed	149	Hoffmann-La Roche	Dec 2014
NCT03350633	TANGO	Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders	P2/P3	completed	118	Tianjin Medical University General Hospital	Nov 2017
NCT03202368	SC	An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)	P3	completed	3	Hoffmann-La Roche	Oct 2017
NCT02043548	TIM	Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	P2	completed	36	Chester Oddis	Oct 2014
NCT03539484		A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors	P1	terminated	26	Hoffmann-La Roche	Jul 2018
NCT03533101		Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation	P1/P2	completed	30	Hospital Universitario Dr. Jose E. Gonzalez	May 2018
NCT03046381	TOCISCH	Tocilizumab in Patients With Schnitzler's Syndrome	P2	completed	8	Karoline Krause	Jul 2017
NCT02477059	TIDOA	Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis	P3	completed	104	Assistance Publique - Hôpitaux de Paris	Nov 2015
NCT02453256	focuSSced	A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)	P3	completed	212	Hoffmann-La Roche	Nov 2015
NCT02101333	TOCITAKA	Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis	P3	completed	18	Assistance Publique - Hôpitaux de Paris	Jun 2014
NCT03522012		Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers	P1	completed	190	Mycenax Biotech Inc.	Oct 2017
NCT02648035	SC	EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis	—	completed	200	Hoffmann-La Roche	Sep 2016
NCT02402686	SIMPACT	Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)	—	completed	353	Hoffmann-La Roche	May 2015
NCT02108600		Tocilizumab for Renal Graft Inflammation	P2	completed	33	Flavio Vincenti	Jun 2014
NCT02353780	MAZERATI	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	P4	terminated	10	Dr. Larry W. Moreland	Mar 2015
NCT02963402		Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab	—	completed	35	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Nov 2016
NCT02206035	AGVD	A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant	P2	completed	45	William R. Drobyski, MD	Dec 2014
NCT01475162		Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease	P1/P2	terminated	14	Medical College of Wisconsin	Aug 2011
NCT02336048	B-CLL	A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities	P1	terminated	38	Hoffmann-La Roche	Jun 2015
NCT02608112		Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year	—	completed	291	Hoffmann-La Roche	Dec 2015
NCT03112213	CONIFER	Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment	—	completed	135	Hoffmann-La Roche	Jan 2017
NCT01782235	ETAP	Efficacy of Tocilizumab in Primary Sjögren's Syndrome.	P2/P3	completed	110	University Hospital, Strasbourg, France	Jul 2013
NCT02469896	TCZALS-001	A Trial of Tocilizumab in ALS Subjects	P2	completed	22	Barrow Neurological Institute	Nov 2015
NCT01791842	TOCIDYS	TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE	P2	completed	19	Hospices Civils de Lyon	May 2013
NCT01791153	GCA	An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)	P3	completed	251	Hoffmann-La Roche	Jul 2013
NCT03062579		A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD	P1/P2	completed	10	Fu-Dong Shi	Feb 2017
NCT02901496		Ectopic Adipose Tissue, Exercise Training and IL-6	N/A	completed	83	Rigshospitalet, Denmark	Aug 2016
NCT02778789	Re-Bone	Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers	—	completed	66	University of Erlangen-Nürnberg Medical School	Oct 2015
NCT02057770		Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	P1	terminated	25	Washington University School of Medicine	Feb 2014
NCT03215407		The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone	P4	unknown	60	Chinese PLA General Hospital	Aug 2017
NCT02676947	TRANSFORM-UK	A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension	P2	completed	29	Papworth Hospital NHS Foundation Trust	Jan 2016
NCT02573012		Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants	P4	completed	314	Hoffmann-La Roche	Mar 2016
NCT03244709		Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.	P4	unknown	15	Hospital of Prato	Jan 2015
NCT01717170	STOP-Uveitis	Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study	P1/P2	unknown	36	University of Nebraska	Mar 2013
NCT02843789	ADIPRAT	Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy	P4	completed	109	Centre Hospitalier Universitaire de Besancon	Mar 2013
NCT02552940	TCZ	An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice	—	completed	140	Hoffmann-La Roche	Oct 2015
NCT02049437	IL-6	AIDS 347: IL-6 Blockade in Treated HIV Infection	P1/P2	completed	34	Case Western Reserve University	Aug 2014
NCT02419937	STAT-MI	Short-Term Application of Tocilizumab Following Myocardial Infarction	N/A	completed	28	Keesler Air Force Base Medical Center	May 2015
NCT01455701		A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)	P1	completed	11	Hoffmann-La Roche	Oct 2012
NCT01904292		A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis	P1	completed	52	Hoffmann-La Roche	Aug 2013
NCT01717859	RASTS	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	P4	completed	74	University of California, Los Angeles	Sep 2014
NCT02034474		Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia	P4	completed	59	New York State Psychiatric Institute	Feb 2014
NCT02011334		A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.	P3	completed	285	Hoffmann-La Roche	Jul 2014
NCT01855789	MTX	A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX	P3	completed	718	Hoffmann-La Roche	Nov 2013
NCT02511067	READ-4	Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study	P2	withdrawn	0	University of Nebraska	Oct 2016
NCT02046616	SC	A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)	P3	completed	133	Hoffmann-La Roche	May 2014
NCT02046603	ACT-MOVE	A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent	P3	completed	162	Hoffmann-La Roche	Mar 2014
NCT02287922		A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis	P2	completed	251	Ablynx, a Sanofi company	Mar 2015
NCT02234960	ACT-POL	Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)	—	completed	102	Hoffmann-La Roche	Aug 2014
NCT02087696		Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis	P4	unknown	122	Spanish Foundation of Rheumatology	May 2014
NCT02682823		Tocilizumab Real-Life Human Factors (RLHFs) Validation Study	P4	completed	91	Hoffmann-La Roche	Mar 2016
NCT01941095		A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis	P3	completed	100	Hoffmann-La Roche	Nov 2013
NCT01941940	RA	A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants	P3	completed	227	Hoffmann-La Roche	Sep 2013
NCT02678988	AI 1000-G2	A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers	P1	completed	189	Hoffmann-La Roche	Feb 2016
NCT02447055		Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma	Early P1	withdrawn	0	Washington University School of Medicine	Dec 2015
NCT01073826	Exil-6	Role of Interleukin-6 in Exercise	N/A	completed	56	University of Zurich	Feb 2010
NCT01910038	HORTOCI	Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.	P2	completed	20	Centre Hospitalier Universitaire Dijon	Nov 2013
NCT01715831	RITACT	A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488	P4	completed	26	Hoffmann-La Roche	Jan 2013
NCT02797769	RA	A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)	—	completed	48,950	Hoffmann-La Roche	Jun 2016
NCT01904279	JIGSAW 117	A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)	P1	completed	52	Hoffmann-La Roche	Jul 2013
NCT01987479	OSCAR	A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis	P3	completed	150	Hoffmann-La Roche	Jan 2014
NCT01668966	NCT01007435	A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)	P3	completed	23	Hoffmann-La Roche	Dec 2013
NCT02404558		Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis	P1	completed	30	Sanofi	May 2015
NCT01995201		A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis	P3	completed	401	Hoffmann-La Roche	Sep 2013
NCT04157010	TREMERA	Tocilizumab REMission in Early RA	P4	completed	20	University of Leeds	May 2013
NCT01331837		A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors	P4	completed	3,080	Hoffmann-La Roche	Aug 2011
NCT02174263		Tocilizumab for Chronic Graft-versus-Host Disease Treatment	P2	withdrawn	0	Fred Hutchinson Cancer Center	Feb 2016
NCT01603355		Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis	P1/P2	terminated	3	Eric B. Suhler	Nov 2013
NCT01396317		Study of Tocilizumab to Treat Polymyalgia Rheumatica	P2	completed	10	Hospital for Special Surgery, New York	Apr 2011
NCT02001987	TOSCA	A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy	P3	completed	139	Hoffmann-La Roche	Jan 2014
NCT01727206		Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease	P2	terminated	3	Ospedale San Raffaele	Nov 2012
NCT01297699	GRC	Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)	P3	completed	32	Hospital Clinico Universitario de Santiago	Mar 2012
NCT02534311	SC	A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)	—	completed	60	Hoffmann-La Roche	Oct 2015
NCT01727986		An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study	P3	completed	11	Hoffmann-La Roche	Mar 2013
NCT02031471		TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment	P3	completed	57	Hoffmann-La Roche	Jan 2014
NCT01734993	RA	A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).	P3	completed	11	Hoffmann-La Roche	Oct 2012
NCT01450137		Tocilizumab for Patients With Giant Cell Arteritis	P2	completed	30	Insel Gruppe AG, University Hospital Bern	Sep 2011
NCT01951170		An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	52	Hoffmann-La Roche	Nov 2013
NCT01532869		A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis	P3	completed	87	Hoffmann-La Roche	Mar 2012
NCT01988012		A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.	P3	completed	100	Hoffmann-La Roche	Jan 2014
NCT01655381		A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis	P3	completed	15	Hoffmann-La Roche	Apr 2012
NCT02888496	TENOR-IMMUNO	Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica	—	completed	40	University Hospital, Brest	Jan 2015
NCT01878318		A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs	P4	withdrawn	0	Hoffmann-La Roche	Jun 2013
NCT01664598		An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis	P3	completed	49	Hoffmann-La Roche	May 2012
NCT01772316		A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	P3	completed	47	Hoffmann-La Roche	Dec 2012
NCT01730456		A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926	P3	completed	13	Hoffmann-La Roche	Oct 2012
NCT01594424		A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation	P1/P2	completed	10	Cedars-Sinai Medical Center	Jun 2012
NCT02097524	PD	Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)	P1	completed	105	Regeneron Pharmaceuticals	Mar 2014
NCT01661140		A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage	P4	terminated	427	Hoffmann-La Roche	Sep 2012
NCT01665430	NCT01007435	A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis	P3	terminated	38	Hoffmann-La Roche	Jul 2012
NCT01362062	RA	Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy	—	completed	110	Hoffmann-La Roche	Oct 2010
NCT01991990		A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers	P4	completed	18	Hoffmann-La Roche	May 2014
NCT01696929		An Open-Label Trial of Tocilizumab in Schizophrenia	P1	completed	8	Brian Miller	Sep 2012
NCT01649804		A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis	P3	completed	12	Hoffmann-La Roche	Jul 2012
NCT01120366	SURPRISE	Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation	P4	completed	233	SURPRISE Study Group	Oct 2009
NCT02721004		Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis	—	completed	592	Hoffmann-La Roche	Mar 2009
NCT01705730		A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy	—	completed	71	Hoffmann-La Roche	Jul 2012
NCT01768572	REGN88	To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)	P3	completed	202	Sanofi	Mar 2013
NCT01617005	RA	A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)	—	completed	50	Hoffmann-La Roche	May 2012
NCT01474291	ACT SOLO	An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice	—	completed	608	Hoffmann-La Roche	Jan 2012
NCT01034137		A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis	P3	completed	317	Hoffmann-La Roche	Jan 2010
NCT01245439		A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	P3	completed	65	Hoffmann-La Roche	Sep 2011
NCT00642460	JIA	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)	P3	completed	112	Hoffmann-La Roche	May 2008
NCT01149057		A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS	P4	completed	145	Hoffmann-La Roche	Oct 2010
NCT01662063	SC	A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)	P3	completed	218	Genentech, Inc.	Aug 2012
NCT01670045		A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	—	completed	43	Hoffmann-La Roche	Mar 2012
NCT01399697		A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	P4	completed	261	Hoffmann-La Roche	Sep 2011
NCT01491074		Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction	P2	completed	120	Oslo University Hospital	Aug 2011
NCT01579006		Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis	—	completed	184	Hoffmann-La Roche	May 2012
NCT01562327		A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis	—	completed	50	Hoffmann-La Roche	Feb 2012
NCT01741688		An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis	—	completed	16	Hoffmann-La Roche	Oct 2012
NCT01587989		A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate	P3	completed	77	Hoffmann-La Roche	Feb 2012
NCT01332994		A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis	P3	completed	519	Hoffmann-La Roche	Mar 2011
NCT01673919		A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study	P3	completed	7	Hoffmann-La Roche	Feb 2012
NCT01007435		A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis	P3	completed	1,162	Hoffmann-La Roche	Oct 2009
NCT01664104		A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting	—	completed	151	Hoffmann-La Roche	Jun 2012
NCT01575769		An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis	P3	terminated	41	Hoffmann-La Roche	Jan 2012
NCT01693653		Tocilizumab for the Treatment of Behcet's Syndrome	P2	terminated	1	NYU Langone Health	Sep 2012
NCT01462162		A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis	—	completed	122	Hoffmann-La Roche	Sep 2011
NCT01232569		A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	656	Hoffmann-La Roche	Mar 2011
NCT01256736		To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	P3	completed	89	JW Pharmaceutical	Mar 2010
NCT01468077		A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment	P2	completed	47	Hoffmann-La Roche	Nov 2011
NCT01637532	PITCH	Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer	P1/P2	completed	21	Leiden University Medical Center	Feb 2011
NCT01667471		A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study	P3	completed	6	Hoffmann-La Roche	Jan 2012
NCT01194414		A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	1,262	Hoffmann-La Roche	Sep 2010
NCT01000441	ROC	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis	P4	completed	300	University Hospital, Strasbourg, France	Dec 2009
NCT01245452	TOMERA	Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate	N/A	completed	30	Patrick Durez	May 2010
NCT01326962		A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF	P3	completed	28	Hoffmann-La Roche	Nov 2011
NCT01347983		Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients	P3	completed	72	Chugai Pharma Taiwan	May 2011
NCT00720798		An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies	P3	completed	2,067	Hoffmann-La Roche	Sep 2005
NCT01219933	ACT-ALONE	A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)	P4	completed	68	Hoffmann-La Roche	Jan 2011
NCT00845832		A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate	P2	terminated	24	Hoffmann-La Roche	Mar 2009
NCT01254331		An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment	P3	completed	51	Hoffmann-La Roche	Feb 2011
NCT01251120		A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis	P4	terminated	2	Hoffmann-La Roche	Nov 2011
NCT00810199		A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment	P3	completed	556	Hoffmann-La Roche	Mar 2009
NCT00988221		A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis	P3	completed	188	Hoffmann-La Roche	Nov 2009
NCT01235507	ALABASTER	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)	P3	completed	71	Hoffmann-La Roche	Feb 2011
NCT01258712		Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients	P3	completed	86	Chugai Pharma Taiwan	Dec 2010
NCT00754572		A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	418	Hoffmann-La Roche	Feb 2009
NCT01283971	MTX	A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor	P4	terminated	96	Hoffmann-La Roche	May 2011
NCT01353859		A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs	P3	completed	39	Hoffmann-La Roche	Mar 2011
NCT00106535	RA	A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)	P3	completed	1,196	Hoffmann-La Roche	Jan 2005
NCT01242488		Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy	P2	completed	221	UCB Pharma	Nov 2010
NCT01163747	VISARA	A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)	P4	completed	91	Genentech, Inc.	Sep 2010
NCT01104480		Tocilizumab for Relapsing Polychondritis	P2	withdrawn	0	McMaster Children's Hospital	May 2010
NCT00721123		A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis	P3	completed	538	Hoffmann-La Roche	Aug 2005
NCT00996606		A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs	P3	completed	58	Hoffmann-La Roche	Oct 2009
NCT00883753	TNF	An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy	P3	completed	934	Hoffmann-La Roche	Mar 2009
NCT01195272		A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.	P4	completed	21	Hoffmann-La Roche	Aug 2010
NCT02809833	RA	Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine	—	completed	850	Hoffmann-La Roche	Jan 2009
NCT01044498		A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis	P3	completed	46	Hoffmann-La Roche	Dec 2009
NCT01119859		A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis	P4	completed	326	Hoffmann-La Roche	May 2010
NCT01041248		Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab	N/A	completed	1	Children's Hospital of Eastern Ontario	Jan 2010
NCT01209689	TNF	A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy	P3	terminated	113	Hoffmann-La Roche	Oct 2010
NCT01209702		A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs	P3	terminated	306	Hoffmann-La Roche	Sep 2010
NCT01089023		A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	P4	completed	95	Hoffmann-La Roche	Jan 2010
NCT01418989		A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers	P1	completed	239	Hoffmann-La Roche	Jul 2011
NCT01183598		A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment	P1	completed	3	Hoffmann-La Roche	Aug 2006
NCT00977106		TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF	P3	completed	103	Hoffmann-La Roche	Jun 2009
NCT01034397		A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs	P4	completed	54	Hoffmann-La Roche	Mar 2010
NCT01610791	REMISSION	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)	P3	completed	121	Hoffmann-La Roche	Mar 2010
NCT01002781		Efficacy and Safety of Tocilizumab in Adult's Still Disease	P2	unknown	10	Tel-Aviv Sourasky Medical Center	Nov 2009
NCT00965653		A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis	P1	completed	29	Hoffmann-La Roche	Aug 2009
NCT00750880	RA	An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.	P3	completed	1,681	Hoffmann-La Roche	Sep 2008
NCT00951275		A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	105	Hoffmann-La Roche	Oct 2009
NCT01214733		A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis	P3	completed	30	Hoffmann-La Roche	Oct 2010
NCT00891020		A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)	P3	completed	886	Hoffmann-La Roche	May 2009
NCT00531817	ROSE	A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis	P3	completed	619	Hoffmann-La Roche	Oct 2007
NCT00996203		A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.	P4	completed	201	Hoffmann-La Roche	Oct 2009
NCT00535782		A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis	P3	completed	132	Hoffmann-La Roche	Oct 2007
NCT01063062	PICTURE	A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)	P3	completed	107	Hoffmann-La Roche	Feb 2010
NCT00887341		A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	P2	completed	76	Hoffmann-La Roche	May 2009
NCT01211834		Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis	P3	completed	90	JW Pharmaceutical	Oct 2009
NCT00862758		Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab	—	no longer available	0	University of Oklahoma	Feb 2009
NCT02010216		A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)	P4	completed	23	Hoffmann-La Roche	Mar 2010
NCT00773461		A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.	P3	completed	209	Hoffmann-La Roche	Oct 2008
NCT00868751		Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis	N/A	terminated	1	Tufts Medical Center	Mar 2009
NCT01010503		A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.	P4	completed	32	Hoffmann-La Roche	Jun 2009
NCT00810277		A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs	P3	completed	14	Hoffmann-La Roche	Nov 2008
NCT00848120		A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis	P3	completed	29	Hoffmann-La Roche	Dec 2008
NCT00754559		A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.	P3	completed	286	Hoffmann-La Roche	Aug 2008
NCT00144586	RA	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP	P3	completed	42	Chugai Pharmaceutical	Mar 2005
NCT00144625		Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	P3	completed	19	Chugai Pharmaceutical	Feb 2005
NCT00144612		Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	P3	completed	60	Chugai Pharmaceutical	Jul 2004
NCT00144534	RA	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP	P3	completed	115	Chugai Pharmaceutical	Jun 2004
NCT00144547	RA	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP	P3	completed	241	Chugai Pharmaceutical	Apr 2004
NCT00144651	RA	Study of MRA in Patients With Rheumatoid Arthritis (RA)	P2	completed	135	Chugai Pharmaceutical	Aug 2001
NCT00380601	RA	PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)	P3	completed	20	Chugai Pharmaceutical	May 2006
NCT00365001		A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.	P1	completed	23	Hoffmann-La Roche	—
NCT00109408		A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis	P3	completed	673	Hoffmann-La Roche	Jul 2005
NCT00106574		A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	1,220	Hoffmann-La Roche	Apr 2005
NCT00106522		A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy	P3	completed	499	Hoffmann-La Roche	May 2005
NCT00106548		A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	P3	completed	623	Hoffmann-La Roche	—
NCT00144521	RA	Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)	P3	completed	127	Chugai Pharmaceutical	Feb 2004
NCT00144508	RA	Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)	P3	completed	306	Chugai Pharmaceutical	Mar 2003
NCT00144573	RA	Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment	N/A	completed	14	Chugai Pharmaceutical	Jan 2005
NCT00144664		Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	P3	completed	19	Chugai Pharmaceutical	Nov 2004
NCT00144599		Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	P3	completed	56	Chugai Pharmaceutical	May 2004
NCT00144560	RA	Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)	N/A	completed	31	Chugai Pharmaceutical	Feb 2005

Tocilizumab clinical trials: frequently asked questions

How many Tocilizumab clinical trials are there?: 466 Tocilizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 54 are actively recruiting participants. 258 are marked completed.
Are Tocilizumab clinical trials recruiting in 2026?: Yes — 54 Tocilizumab trials are actively recruiting in 2026, with 191 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tocilizumab being studied for?: Tocilizumab is being studied for Rheumatoid Arthritis, COVID-19, Juvenile Idiopathic Arthritis, Giant Cell Arteritis, Multiple Myeloma and 426 more. The trials are grouped by indication on this page.
What phase is Tocilizumab in?: Tocilizumab clinical trials span 53 Phase 4, 130 Phase 3, 99 Phase 2, 64 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tocilizumab clinical trials?: The lead sponsor across the most Tocilizumab trials is Hoffmann-La Roche, with 199 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tocilizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 16, 2026.

Related pages on Hipa.ai:

Tocilizumab overview Tocilizumab evidence & publications